[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 61309
1. Souza-Menezes J, Morales MM: CFTR structure and function: is there a role in the kidney? Biophys Rev; 2009 Mar;1(1):3-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CFTR structure and function: is there a role in the kidney?
  • Despite of the expression of CFTR in the kidney, patients with CF do not present major renal dysfunction, but it is known that both the urinary excretion of proteins and renal capacity to concentrate and dilute urine are altered in these patients.
  • CFTR mRNA is expressed in all nephron segments of rat and human, and this abundance is more prominent in renal cortex and outer medulla renal areas.
  • CFTR protein was detected in apical surface of both proximal and distal tubules of rat kidney but not in the outer medullary collecting ducts.
  • ATP transport by CFTR could be involved in the control of other ion transporters such as Na<sup>+</sup> (ENaC) and K<sup>+</sup> (renal outer medullary potassium) channels, especially in TAL and CCD.
  • In the kidney, CFTR also might be involved in the endocytosis of low-molecular-weight proteins by proximal tubules.
  • This review is focused on the CFTR function and structure, its role in the renal physiology, and its modulation by hormones involved in the control of extracellular fluid volume.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Physiol Rev. 1999 Jan;79(1 Suppl):S175-91 [9922381.001]
  • [Cites] Nephron. 1975;15(3-5):223-49 [1101087.001]
  • [Cites] Science. 1989 Sep 8;245(4922):1059-65 [2772657.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15419-25 [11861646.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 2):F817-33 [9612319.001]
  • [Cites] J Clin Invest. 1998 Jul 1;102(1):15-21 [9649552.001]
  • [Cites] Am J Physiol. 1984 Jun;246(6 Pt 2):F745-56 [6377912.001]
  • [Cites] Am J Physiol. 1996 Jun;270(6 Pt 2):F1038-48 [8764323.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 2):F552-9 [10516279.001]
  • [Cites] Pflugers Arch. 1999 Oct;438(5):621-7 [10555558.001]
  • [Cites] Pflugers Arch. 2002 May;444(1-2):193-201 [11976932.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):581-6 [16989640.001]
  • [Cites] Hosp Pract (Off Ed). 1990 Oct 15;25(10):47-57 [1698801.001]
  • [Cites] Methods Enzymol. 2005;400:542-57 [16399369.001]
  • [Cites] FASEB J. 1992 Jun;6(9):2660-6 [1377140.001]
  • [Cites] Nature. 1985 Nov 28-Dec 4;318(6044):380-2 [2999611.001]
  • [Cites] Annu Rev Physiol. 1997;59:413-36 [9074771.001]
  • [Cites] Science. 1989 Sep 8;245(4922):1066-73 [2475911.001]
  • [Cites] Am J Physiol. 1999 Apr;276(4 Pt 1):C827-37 [10199813.001]
  • [Cites] J Membr Biol. 2004 Apr 1;198(3):113-24 [15216413.001]
  • [Cites] Science. 1995 Nov 17;270(5239):1166-70 [7502040.001]
  • [Cites] EMBO Rep. 2001 Nov;2(11):1047-51 [11606421.001]
  • [Cites] An Acad Bras Cienc. 2000 Sep;72(3):399-406 [11028104.001]
  • [Cites] J Gen Physiol. 2002 Jul;120(1):71-85 [12084777.001]
  • [Cites] EMBO J. 1982;1(8):945-51 [6329717.001]
  • [Cites] J Physiol. 1998 May 1;508 ( Pt 3):825-36 [9518736.001]
  • [Cites] Pflugers Arch. 2000 Jun;440(2):193-201 [10898518.001]
  • [Cites] Nat Struct Mol Biol. 2004 Oct;11(10):918-26 [15452563.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Apr;3(4):256-66 [11994745.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):682-3 [8441459.001]
  • [Cites] Pflugers Arch. 2001 Nov;443(2):202-11 [11713645.001]
  • [Cites] Pflugers Arch. 2003 Jan;445(4):504-12 [12548397.001]
  • [Cites] Cell Physiol Biochem. 2008;22(1-4):93-100 [18769035.001]
  • [Cites] EMBO J. 1998 Feb 16;17(4):898-908 [9463368.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):503-68 [11917096.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Oct;287(4):F722-31 [15161604.001]
  • [Cites] J Gen Physiol. 2003 Sep;122(3):333-48 [12939393.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1317-72 [10508236.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8083-8 [8755607.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):G491-8 [9950824.001]
  • [Cites] Kidney Int. 2001 Aug;60(2):455-61 [11473626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6832-6 [7542778.001]
  • [Cites] Curr Med Chem. 2006;13(7):771-82 [16611066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9262-6 [1718002.001]
  • [Cites] Kidney Int. 2006 Feb;69(3):440-9 [16514429.001]
  • [Cites] Physiol Rev. 1985 Jul;65(3):760-97 [2409564.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):876-80 [15729345.001]
  • [Cites] Am J Physiol. 1999 Dec;277(6 Pt 2):F826-31 [10600928.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5235-42 [9478979.001]
  • [Cites] Respir Physiol. 1997 Feb;107(2):173-80 [9108631.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2008 Jan-Feb;43(1):3-36 [18307107.001]
  • [Cites] Am J Physiol. 1996 Sep;271(3 Pt 2):F723-35 [8853436.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):196-9 [10646604.001]
  • [Cites] Braz J Med Biol Res. 1999 Aug;32(8):1021-8 [10454765.001]
  • [Cites] Science. 1992 May 8;256(5058):774-9 [1375392.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14165-71 [9603917.001]
  • [Cites] J Mol Biol. 1999 Oct 22;293(2):381-99 [10529352.001]
  • [Cites] Am J Physiol. 1996 Feb;270(2 Pt 1):C585-92 [8779923.001]
  • [Cites] Nature. 2006 Mar 23;440(7083):477-83 [16554808.001]
  • [Cites] Am J Physiol. 1992 Aug;263(2 Pt 1):C267-86 [1381146.001]
  • [Cites] Science. 1995 Aug 11;269(5225):847-50 [7543698.001]
  • [Cites] J Endocrinol. 2006 Apr;189(1):155-65 [16614390.001]
  • [Cites] Cell Physiol Biochem. 2007;20(5):455-64 [17762172.001]
  • [Cites] Annu Rev Physiol. 1993;55:609-30 [7682047.001]
  • [Cites] Cell. 1992 Feb 21;68(4):809-18 [1371239.001]
  • [Cites] J Membr Biol. 1999 Mar 1;168(1):1-8 [10051684.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):351-87 [18391167.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):726-30 [8441467.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G663-70 [14630642.001]
  • [Cites] Purinergic Signal. 2008 Jun;4(2):125-37 [18368527.001]
  • [Cites] Ophthalmic Genet. 2003 Jun;24(2):75-80 [12789571.001]
  • [Cites] Science. 1995 Apr 21;268(5209):426-9 [7716548.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1 Suppl):S145-66 [9922379.001]
  • [Cites] Cell. 1995 Jun 30;81(7):1063-73 [7541313.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 2):F843-8 [9374850.001]
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):707-18 [17287432.001]
  • [Cites] Nature. 2001 Nov 29;414(6863):558-61 [11734858.001]
  • [Cites] J Physiol. 2000 Apr 1;524 Pt 1:77-90 [10747185.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21111-4 [11964392.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2674-9 [9482946.001]
  • [Cites] Pflugers Arch. 2009 Apr;457(6):1227-36 [18839205.001]
  • [Cites] Physiol Rev. 1998 Jan;78(1):227-45 [9457174.001]
  • [Cites] J Bioenerg Biomembr. 2005 Dec;37(6):475-9 [16691486.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Jun;280(6):F945-63 [11352834.001]
  • [Cites] Annu Rev Physiol. 2005;67:701-18 [15709975.001]
  • [Cites] Jpn J Physiol. 1994;44 Suppl 2:S1-2 [7752510.001]
  • [Cites] Biol Pharm Bull. 1999 Oct;22(10):1027-33 [10549850.001]
  • [Cites] Nature. 1996 Sep 26;383(6598):340-3 [8848047.001]
  • [Cites] Jpn J Physiol. 1994;44 Suppl 2:S3-8 [7752544.001]
  • [Cites] FEBS Lett. 2006 Feb 13;580(4):1103-11 [16387301.001]
  • [Cites] Pflugers Arch. 2003 Jan;445(4):513-21 [12548398.001]
  • [Cites] Cell Physiol Biochem. 2007;20(1-4):83-90 [17595518.001]
  • [Cites] EMBO J. 2005 Jun 1;24(11):1901-10 [15889153.001]
  • [Cites] Structure. 2001 Jul 3;9(7):571-86 [11470432.001]
  • (PMID = 28510151.001).
  • [ISSN] 1867-2450
  • [Journal-full-title] Biophysical reviews
  • [ISO-abbreviation] Biophys Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; CFTR / Chloride channel / ENaC / Kidney / Nephron / ROMK / TNR-CFTR
  •  go-up   go-down


2. Lameire N, Van Biesen W, Hoste E, Vanholder R: The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI. NDT Plus; 2008 Dec;1(6):392-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI.
  • This narrative clinical review in two parts discusses the prevention of clinical acute kidney injury (AKI).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Aug 21;288(7):862-71 [12186604.001]
  • [Cites] Anesth Analg. 2008 Jun;106(6):1627-32 [18499589.001]
  • [Cites] Intensive Care Med. 2008 Apr;34(4):659-63 [18214429.001]
  • [Cites] Am J Nephrol. 2007;27(1):55-62 [17259694.001]
  • [Cites] Acta Clin Belg. 2007;62 Suppl 2:412-6 [18284012.001]
  • [Cites] Crit Care Med. 2006 May;34(5):1402-7 [16540963.001]
  • [Cites] Nephrol Dial Transplant. 2007 Nov;22(11):3097-101 [17617650.001]
  • [Cites] J Am Coll Cardiol. 2007 Mar 27;49(12):1283-8 [17394959.001]
  • [Cites] Kidney Int. 1997 Oct;52(4):886-94 [9328926.001]
  • [Cites] Curr Opin Crit Care. 2002 Dec;8(6):509-14 [12454534.001]
  • [Cites] Crit Care Med. 2008 Jan;36(1 Suppl):S75-88 [18158481.001]
  • [Cites] Crit Care. 2007;11(2):R31 [17331245.001]
  • [Cites] Br J Radiol. 1999 Jul;72 (859):701-3 [10624328.001]
  • [Cites] J Trauma. 2006 Sep;61(3):624-8 [16966998.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2564-75 [16714767.001]
  • [Cites] J Clin Invest. 1983 Mar;71(3):726-35 [6826732.001]
  • [Cites] Circulation. 2007 Mar 13;115(10 ):1211-7 [17309916.001]
  • [Cites] JAMA. 2008 Aug 27;300(8):933-44 [18728267.001]
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):860-7 [17301189.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1274-81 [18463172.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):10-8 [18057306.001]
  • [Cites] J Am Soc Nephrol. 2008 Jul;19(7):1360-70 [18385426.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000567 [17943746.001]
  • [Cites] BMJ. 2004 Aug 28;329(7464):480 [15289273.001]
  • [Cites] J Am Coll Cardiol. 2008 Aug 19;52(8):599-604 [18702961.001]
  • [Cites] Crit Care Med. 2004 Mar;32(3):691-9 [15090949.001]
  • [Cites] J Am Soc Nephrol. 2008 Jul;19(7):1253-5 [18508961.001]
  • [Cites] J Am Coll Cardiol. 1999 Feb;33(2):403-11 [9973020.001]
  • [Cites] Intensive Care Med. 2002 Apr;28(4):392-8 [11967591.001]
  • [Cites] Crit Care. 2008;12(1):R29 [18312617.001]
  • [Cites] Nephrol Dial Transplant. 2008 Apr;23 (4):1233-40 [18256017.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1266-73 [18667735.001]
  • [Cites] Crit Care Med. 2008 Aug;36(8):2316-21 [18596625.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2006 May;15(3):285-90 [16609296.001]
  • [Cites] Arch Intern Med. 1979 Jul;139(7):801-5 [454069.001]
  • [Cites] Anesth Analg. 2005 May;100(5):1518-24, table of contents [15845718.001]
  • [Cites] Nephron Clin Pract. 2007;105(2):c77-83 [17143010.001]
  • [Cites] J Am Soc Nephrol. 2004 Jul;15(7):1862-7 [15213274.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):125-39 [18184958.001]
  • [Cites] JAMA. 2006 Jun 21;295(23):2765-79 [16788132.001]
  • [Cites] J Am Coll Cardiol. 2006 Aug 15;48(4):692-9 [16904536.001]
  • [Cites] J Am Coll Cardiol. 2007 Aug 14;50(7):584-90 [17692741.001]
  • [Cites] Clin J Am Soc Nephrol. 2007 Mar;2(2):356-65 [17699435.001]
  • [Cites] Arch Intern Med. 2008 Jun 23;168(12):1325-32 [18574090.001]
  • [Cites] Circulation. 2007 Jun 26;115(25):3189-96 [17562951.001]
  • [Cites] J Am Soc Nephrol. 2008 Mar;19(3):571-8 [18235100.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):491-9 [12571256.001]
  • [Cites] Nephron Clin Pract. 2003 Jan;93(1):C29-34 [12411756.001]
  • [Cites] Circulation. 2006 Apr 11;113(14):1799-806 [16606801.001]
  • [Cites] Ren Fail. 1997 Sep;19(5):647-53 [9380883.001]
  • [Cites] Crit Care Med. 2008 Apr;36(4 Suppl):S216-23 [18382197.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 May;3(3):864-8 [18287251.001]
  • [Cites] Kidney Int. 2003 Feb;63(2):600-6 [12631124.001]
  • [Cites] N Engl J Med. 2006 May 25;354(21):2213-24 [16714768.001]
  • [Cites] Coron Artery Dis. 2008 Sep;19(6):413-9 [18955835.001]
  • [Cites] Crit Care Med. 2004 Mar;32(3):858-73 [15090974.001]
  • [Cites] Invest Radiol. 2006 Nov;41(11):815-21 [17035872.001]
  • [Cites] Acta Clin Belg. 2007;62 Suppl 2:346-52 [18283997.001]
  • [Cites] Ann Med. 2005;37(1):13-25 [15902843.001]
  • [Cites] J Trauma. 1994 Aug;37(2):214-9 [8064919.001]
  • [Cites] Anesth Analg. 2001 Oct;93(4):817-22 [11574339.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1025-32 [7675044.001]
  • [Cites] Chest. 2008 Jan;133(1):252-63 [18187750.001]
  • [Cites] Semin Respir Crit Care Med. 2007 Dec;28(6):596-603 [18095223.001]
  • [Cites] J Am Coll Cardiol. 2008 Apr 15;51(15):1419-28 [18402894.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] J Am Coll Cardiol. 2008 Jan 1;51(1):89-90 [18174044.001]
  • [Cites] Med Mycol. 2008 Mar;46(2):97-112 [18324488.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):449-61 [16452557.001]
  • [Cites] N Engl J Med. 1994 Nov 24;331(21):1416-20 [7969280.001]
  • [Cites] Chest. 2007 Jan;131(1):300-8 [17218591.001]
  • [Cites] Kidney Int. 1996 Feb;49(2):314-26 [8821813.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Jul;3(4):962-7 [18354074.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1368-77 [11794169.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2008 Mar;22(1):135-49 [18494393.001]
  • [Cites] Shock. 2006 Dec;26(6):551-7 [17117128.001]
  • [Cites] Arch Intern Med. 2002 Feb 11;162(3):329-36 [11822926.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):273-80 [17989201.001]
  • [Cites] Mil Med. 1999 May;164(5):366-9 [10332179.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2004 Mar;18(1):37-52 [14760873.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):111-24 [18184957.001]
  • [Cites] CMAJ. 2005 Oct 25;173(9):1054-65 [16247103.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2247-56 [15163774.001]
  • [Cites] J Am Soc Nephrol. 2000 Aug;11(8):1553-61 [10906171.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):1052-63 [16525142.001]
  • [Cites] Chest. 2005 Aug;128(2):848-54 [16100177.001]
  • [Cites] Chest. 1998 Dec;114(6):1570-4 [9872190.001]
  • [Cites] Crit Care Med. 2008 Jun;36(6):1937-49 [18496365.001]
  • [Cites] Nephrol Dial Transplant. 2007 Oct;22(10):2849-55 [17604310.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):284-94 [18283206.001]
  • [Cites] Nephrol Dial Transplant. 2006 Jun;21(6):i11-23 [16723348.001]
  • [Cites] JAMA. 2004 May 19;291(19):2328-34 [15150204.001]
  • [Cites] Crit Care Med. 2007 Dec;35(12):2740-6 [17893629.001]
  • [Cites] Chest. 2005 Oct;128(4):1902-3 [16236833.001]
  • [Cites] Acta Clin Belg. 2007;62 Suppl 2:408-11 [18284011.001]
  • [Cites] J Nephrol. 2005 Jan-Feb;18(1):54-60 [15772923.001]
  • [Cites] Clin Infect Dis. 2001 Mar 1;32(5):686-93 [11229835.001]
  • [Cites] N Engl J Med. 2006 Oct 19;355(16):1699-713 [17050894.001]
  • [Cites] Am Heart J. 2004 Feb;147(2):331-8 [14760333.001]
  • [Cites] J Am Coll Cardiol. 2006 Sep 5;48(5):924-30 [16949481.001]
  • [Cites] JAMA. 2008 Aug 27;300(8):963-5 [18728273.001]
  • [Cites] Kidney Int. 2008 Feb;73(4):379-81 [18235520.001]
  • [Cites] Semin Dial. 2007 May-Jun;20(3):179-85 [17555477.001]
  • [Cites] Int J Artif Organs. 2008 Feb;31(2):111-26 [18311728.001]
  • [Cites] Int J Artif Organs. 2008 Feb;31(2):94-5 [18311726.001]
  • [Cites] Int J Artif Organs. 2008 Feb;31(2):96-110 [18311727.001]
  • (PMID = 28657002.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Keywords] NOTNLM ; acute kidney injury / fluid therapy / prevention / tight glycaemia control / volume expansion
  •  go-up   go-down


3. Shashkova EV, Spencer JF, Wold WS, Doronin K: Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic Adenovirus. Mol Ther; 2007 Mar;15(3):598-607
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antitumor activity of KD3-IFN was significantly higher than that of a control vector in established human hepatocellular carcinoma tumors in immunodeficient mice and in hamster kidney cancer tumors in immunocompetent Syrian hamsters.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182898.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Oguzhan N, Unal A, Yarlıogluesi M, Oymak O, Utas C: Central venous catheter-related right atrial thrombus in two kidney transplantation recipients. NDT Plus; 2010 Jun;3(3):306-309

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central venous catheter-related right atrial thrombus in two kidney transplantation recipients.
  • There is an increased risk of thromboembolism following renal transplantation.
  • However, a right atrial thrombosis is rarely reported in renal transplant recipients.
  • Here, we report two cases of renal transplant recipients in whom a right atrial thrombus developed after kidney transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Transplant. 2008 Mar;12(2):251-5 [18179641.001]
  • [Cites] Angiology. 2001 Jun;52(6):425-8 [11437034.001]
  • [Cites] Am Heart J. 1998 Mar;135(3):457-62 [9506332.001]
  • [Cites] Intensive Care Med. 2003 Oct;29(10):1829-32 [12897992.001]
  • [Cites] J Pediatr. 1982 Jan;100(1):149-52 [6799632.001]
  • [Cites] South Med J. 2008 Jun;101(6):662-3 [18528224.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2008 Jan;19(1):90-3 [18087132.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1895-8 [1326397.001]
  • [Cites] Eur Heart J. 1993 Jan;14 (1):138-40 [8432282.001]
  • [Cites] Surg Gynecol Obstet. 1979 Jun;148(6):871-5 [109934.001]
  • (PMID = 28657063.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; anticoagulant therapy / central venous catheter / kidney transplantation / right atrial thrombus / surgery treatment
  •  go-up   go-down


5. Kusaka M, Kuroyanagi Y, Mori T, Nagaoka K, Sasaki H, Maruyama T, Hayakawa K, Shiroki R, Kurahashi H, Hoshinaga K: Global Expression Profiles in 1-Hour Biopsy Specimens of Human Kidney Transplantation from Donors after Cardiac Death. Cell Transplant; 2009 May/Jun;18(5-6):647-656

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global Expression Profiles in 1-Hour Biopsy Specimens of Human Kidney Transplantation from Donors after Cardiac Death.
  • Because of the worldwide shortage of renal grafts, kidney transplantation (KTx) from donors after cardiac death (DCD) is an alternative way to obtain KTx from brain-dead donors.
  • In an attempt to characterize etiology of DGF, genome-wide gene expression profiling was performed using renal biopsy samples performed at 1 h after KTx from DCD and the data were compared with those of KTx from living donors (LD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880652.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Delayed graft function / Donation after cardiac death / Gene expression / Kidney transplantation
  •  go-up   go-down


6. Pakkyara A, Mohsin N, Budruddin M, Mohammad AJE, Mohammad K: Calcium Kinetic in a patient with acute renal failure due to Rhabdomyolysis. A Case Report and Review of Literature. Oman Med J; 2010 Oct;25(4):e013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium Kinetic in a patient with acute renal failure due to Rhabdomyolysis. A Case Report and Review of Literature.
  • Hypercalcemia may follow hypocalcemia in the course of acute renal failure (also named now as acute kidney injury) secondary to rhabdomyolysis.
  • The patient was discharged 3 weeks after admission with a recovered clinical condition, improved renal functions and normal calcemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care. 2007;11(2):R31 [17331245.001]
  • [Cites] Clin Nephrol. 1993 Jan;39(1):22-7 [8428403.001]
  • [Cites] Crit Care. 2005 Apr;9(2):158-69 [15774072.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Jul;63(1):137-42 [3011837.001]
  • [Cites] Am J Kidney Dis. 2004 Mar;43(3):e31-5 [14981639.001]
  • [Cites] Br Med J. 1941 Mar 22;1(4185):427-32 [20783577.001]
  • [Cites] N Engl J Med. 1981 Jul 16;305(3):117-23 [6894630.001]
  • [Cites] J Am Soc Nephrol. 2000 Aug;11(8):1553-61 [10906171.001]
  • (PMID = 28845216.001).
  • [ISSN] 1999-768X
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Keywords] NOTNLM ; Acute kidney injury / Hypercalcemia / Hypocalcemia / Rhabdomyolysis
  •  go-up   go-down


7. Fabbian F, Ricci F, De Giorgi A, Forcellini S, Scanelli G: The May-Hegglin anomaly in a kidney transplant recipient. NDT Plus; 2010 Jun;3(3):312

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The May-Hegglin anomaly in a kidney transplant recipient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 1992 Jul;40(3):216-21 [1319112.001]
  • [Cites] Semin Thromb Hemost. 2009 Mar;35(2):189-203 [19408192.001]
  • [Cites] Am J Kidney Dis. 2009 Oct;54(4):732-40 [19726116.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2009 Nov;20(6):1076-8 [19861875.001]
  • (PMID = 28657035.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; May–Hegglin anomaly / macrothrombocytes / renal failure / thrombocytopaenia
  •  go-up   go-down


8. Jong WH, Burger MC, Verheijen MA, Geertsma RE: Detection of the Presence of Gold Nanoparticles in Organs by Transmission Electron Microscopy. Materials (Basel); 2010 Sep 27;3(9):4681-4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the liver and spleen of animals treated with 10 nm gold nanoparticles, groups of nanoparticles were observed that could be positively identified by Energy Dispersive X-ray (EDX) analysis to contain gold, while nanoparticles could not be detected in the heart, kidney and brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Angew Chem Int Ed Engl. 2007;46(30):5754-6 [17591736.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]
  • [Cites] Environ Sci Technol. 2006 Jul 15;40(14):4353-9 [16903270.001]
  • [Cites] Biomaterials. 2008 Apr;29(12):1912-9 [18242692.001]
  • [Cites] J Control Release. 2009 Oct 1;139(1):81-4 [19538994.001]
  • [Cites] Part Fibre Toxicol. 2007 Oct 19;4:10 [17949501.001]
  • [Cites] Nanomedicine. 2009 Jun;5(2):162-9 [19217434.001]
  • [Cites] J Pharm Sci. 1995 Apr;84(4):493-8 [7629743.001]
  • [Cites] Biomaterials. 1999 Jul;20(14):1269-75 [10403044.001]
  • [Cites] J Control Release. 2006 Sep 12;114(3):343-7 [16876898.001]
  • (PMID = 28883347.001).
  • [ISSN] 1996-1944
  • [Journal-full-title] Materials (Basel, Switzerland)
  • [ISO-abbreviation] Materials (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; gold nanoparticles / tissue distribution / transmission electron microscopy
  •  go-up   go-down


9. Habib SL, Danial E, Nath S, Schneider J, Jenkinson CP, Duggirala R, Abboud HE, Thameem F: Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis. Cancer Biol Ther; 2008 Jan;7(1):23-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis.
  • Genetic variations in OGG1 gene have been shown to modulate DNA repair capacity and are related risk of tumor development.
  • The purpose of this study is to determine whether genetic variants in OGG1 play a role in susceptibility to angiomyolipoma, a benign kidney tumor associated with tuberous sclerosis complex (TSC) patients.
  • We also assessed the presence of oxidative DNA damage in kidney section from normal healthy subjects, normal kidney tissue from TSC patients and kidney angiomyolipoma tissue from TSC patients by immunostaining for 8-oxodG.
  • 8-OxodG staining was highly abundant in kidney angiomyolipoma tissue from TSC patients compared to weak staining in uninvolved tissue from the same TSC patients or normal kidney from healthy subjects.
  • [MeSH-major] Angiomyolipoma / genetics. DNA Glycosylases / genetics. Kidney Neoplasms / genetics. Polymorphism, Genetic. Tuberous Sclerosis / genetics

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17932460.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK079195
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


10. Davalli AM, Perego L, Bertuzzi F, Finzi G, La Rosa S, Blau A, Placidi C, Nano R, Gregorini L, Perego C, Capella C, Folli F: Disproportionate Hyperproinsulinemia, β-Cell Restricted Prohormone Convertase 2 Deficiency, and Cell Cycle Inhibitors Expression by Human Islets Transplanted into Athymic Nude Mice: Insights into Nonimmune-Mediated Mechanisms of Delayed Islet Graft Failure. Cell Transplant; 2008 Dec;17(12):1323-1336
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To learn more about nonimmune-mediated islet graft failure, we transplanted different preparations (preps) of isolated human islets under the kidney capsule of streptozotocin (STZ)-diabetic nude mice.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876095.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Athymic nude mice / Islet transplantation / Prohormone convertase 2 (PC2) / Proinsulin processing / p16INK4 / p21WAF1 / p27Kip1
  •  go-up   go-down


11. Larocque M, Syme A, Fallone BG: Sci-Sat AM(1): Imaging-01: Tumour and normal tissue T2 and ADC distributions for a mouse model at 9.4T. Med Phys; 2008 Jul;35(7Part3):3414
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sci-Sat AM(1): Imaging-01: Tumour and normal tissue T2 and ADC distributions for a mouse model at 9.4T.
  • We are currently using mouse models of human glioblastoma multiforme (GBM) to study tumour response to ionizing radiation by MRI at 9.4T.
  • Utilizing conventional imaging techniques coupled with quantitative measurements of transverse relaxation time (T2) and apparent diffusion coefficient (ADC), we monitor changes during tumour growth and subsequent changes after single-fraction radiotherapy.
  • In addition to tumour parameters, we have measured T2 and ADC in other structures that appear in the same transverse slices as tumour tissue.
  • Here we report the measured distributions of T2 and ADC in tumour and in normal tissues that are likely to be encountered during MR imaging of tumour xenografts in mice, including liver, kidney, fat, skeletal muscle, spinal cord, and brain.
  • Knowledge of parameter distributions in tumour is important because recent studies have suggested that the T2 and ADC responses after therapy may be the result of large shifts in smaller isolated pockets of tumour, rather than more moderate shifts in T2 and ADC over the whole tumour volume.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512910.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Diffusion / Ionizing radiation / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Relaxation times / Time measurement / Tissues
  •  go-up   go-down


12. Kuge H, Ohashi K, Yokoyama T, Kanehiro H, Hisanaga M, Koyama F, Bumgardner GL, Kosai KI, Nakajima Y: Genetic Modification of Hepatocytes towards Hepatocyte Transplantation and Liver Tissue Engineering. Cell Transplant; 2006 Jan;15(1):1-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To establish if the isolated hepatocytes could be used as a source for cell-based therapies, we transplanted the Ad-transduced hepatocytes into the liver or under the kidney capsule.
  • We also confirmed that these Ad-transduced hepatocytes have ability to survive long term and were able to engineer a biologically active hepatic tissue under the kidney capsule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28871876.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenoviral vector / Ex vivo gene therapy / Gene modification / Hepatocyte transplantation / Liver tissue engineering
  •  go-up   go-down


13. Roth AE, Sönmez T, Ünver MU: A Kidney Exchange Clearinghouse in New England. Am Econ Rev; 2005 May;95(2):376-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Kidney Exchange Clearinghouse in New England.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29125723.001).
  • [ISSN] 0002-8282
  • [Journal-full-title] The American economic review
  • [ISO-abbreviation] Am Econ Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Norum J, Nieder C, Kondo M: Sunitinib, sorafenib, temsirolimus, or bevacizumab in the treatment of metastatic renal cell carcinoma (RCC): A review of health economic evaluations. J Clin Oncol; 2009 May 20;27(15_suppl):e17539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib, sorafenib, temsirolimus, or bevacizumab in the treatment of metastatic renal cell carcinoma (RCC): A review of health economic evaluations.
  • : e17539 Background: Renal cell carcinoma (RCC) is the most prevalent kidney cancer and the 5-year overall survival figure in metastatic disease (mRCC) is about 10%.
  • The PubMed, ASCO abstracts, Google, and the Igaku Chuo Zasshi databases were searched in November 2008 with key terms: kidney, renal, cancer, cost, sunitinib, sorafenib, temsirolimus, and bevacizumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Beaumont J, Cella D, Hutson T, Bracarda S, Grünwald V, Thompson J, Ravaud A, Urbanowitz G, Hollaender N, Motzer R: Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):e17516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients.
  • : e17516 Background: Patient-reported outcomes (PRO), including health-related quality of life (HRQL), were assessed in a Phase III trial of everolimus in metastatic renal cell carcinoma (mRCC) patients.
  • Patients completed the FACT-Kidney Symptom Index- Disease Related Symptoms (FKSI-DRS) and EORTC-QLQ C30 at baseline and monthly during treatment.
  • Secondary analyses considered tumor progressions that occurred prior to deterioration or censoring date as FKSI deterioration events and compared time to PRO deterioration by tumor progression.
  • Secondary analyses suggest a delay in deterioration in kidney cancer related symptoms via tumor control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Christiansen CF, Johansen MB, Christensen S, Langeberg W, Fryzek JP, Toft Sørensen H: Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark. J Clin Oncol; 2009 May 20;27(15_suppl):9570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark.
  • : 9570 Background: Although cancer patients may be at increased risk for acute kidney injury (AKI), which could then reduce their likelihood of receiving optimal therapeutic management and supportive care, the occurrence of AKI among newly diagnosed cancer patients has not been well-described.
  • Therefore, we examined the incidence of AKI within the first year after cancer diagnosis to estimate the magnitude of this risk and better understand which patients are at greatest risk.
  • AKI was defined according to the Risk/ Injury/ Failure/ Loss/ End-stage-renal-disease (RIFLE) criteria.
  • Baseline sCr was defined as the lowest sCr in the year before cancer diagnosis.
  • We compared this value to the highest sCr on record during the first year following cancer diagnosis to identify those who experienced an AKI.
  • Incidence was highest among patients aged 80 years or older (531 per 1,000 person-years, 95% CI 464-606) and in those with cancer of the liver (1,221, 95%CI 676-2,205), pancreas (1,472, 95%CI 1,130-1,917), or kidney (1,254, 95%CI 974-1,616), or with multiple myeloma (855, 95%CI 538-1,356).
  • Our study showed that over 20% of cancer patients may experience acute kidney injury in the first year after diagnosis.
  • Older patients and those with cancer of the liver, pancreas, or kidney, or with multiple myeloma are especially at risk for AKI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963659.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gupta S, Parsa V, Heilbrun L, Smith D, Dickow B, Heath E, Vaishampayan U: Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). J Clin Oncol; 2009 May 20;27(15_suppl):5108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI).
  • : 5108 Background: S, T (temsirolimus) and E (everolimus) are primarily metabolized in the liver, while the metabolism of B is unclear.
  • There are limited data on the clinical toxicity profile and efficacy of these agents in pts with RI.
  • METHODS: The primary objective was to assess the safety and efficacy of S, B, T and E in pts with RI.
  • Pts with a calculated creatinine clearance (CrCl) of ≤ 60ml/min [chronic kidney disease stage 3 or higher per K/DOQI guidelines by the National Kidney Foundation] were deemed to have RI.
  • Data on safety and efficacy of the therapy were collected and analyzed with respect to renal function.
  • RESULTS: 19 of 51 (37%) pts had RI.
  • Pts with RI had a higher median rise in blood pressure (BP) with S and B than pts with normal renal function.
  • Patients with RI had an increased incidence of rash and higher dose interruption rates with m-TOR inhibitors.
  • No major differences in toxicities including cardiac, thyroid, renal, lipid profile abnormalities or hyperglycemia were observed.
  • CONCLUSIONS: More than a third of pts with mRCC receiving targeted therapy have RI, hence highlighting the importance of evaluating tolerability of therapies in pts with RI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964365.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pandurengan RK, Strom SS, Trent J 2nd: Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients.
  • : 10567 Background: The objective of this study is to investigate the characteristics and survival rate of patients with Gastrointestinal Stromal Tumor (GIST) associated with other primary malignancies.
  • Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.
  • Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.
  • Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.
  • The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).
  • The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).
  • Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.
  • The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ruiz-Argüelles GJ, Gómez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, David-Gómez-Rangel J, García-Ruiz-Esparza MA, López-Martínez B, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH: Extramedullary Leukemic Relapses Following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning. Int J Hematol; 2005 Oct;82(3):262

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EMR presented 60 to 1010 days after the allograft and appeared in 3 cases as subcutaneous nodules in different parts of the body, in the vertebrae in 3 cases, and in the kidney and the breast in 1 case each.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28401517.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Allograft / Extramedullary / Leukemia / Nonmyeloablative / Relapse
  •  go-up   go-down


20. Chen M, Matsuda H, Wang L, Watanabe T, Kimura MT, Igarashi J, Wang X, Sakimoto T, Fukuda N, Sawa M, Nagase H: Pretranscriptional Regulation of Tgf-β1 by PI Polyamide Prevents Scarring and Accelerates Wound Healing of the Cornea After Exposure to Alkali. Mol Ther; 2010 Mar;18(3):519-527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GB1201 significantly inhibited the rat Tgf-β1 gene promoter activity in HEK (human embryonic kidney) 293 cells in a concentration-dependent manner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182879.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, Braghetta P, van Ommen GB, de Kimpe S, Ferlini A, Aartsma-Rus A, van Deutekom JC: Preclinical PK and PD Studies on 2'-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model. Mol Ther; 2010 Jun;18(6):1210-1217

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After i.v. administration, the oligonucleotide peak levels in plasma, liver, and kidney were higher than after s.c. or i.p. injections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178497.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Han B, Shen J, Gao Z: Treatment guided by ERCC1, RRM1, and BRCA1 protein expression in patients with advanced-stage NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):e19094

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eligibility: Main inclusion criteria: Stage IV or stage IIIB NSCLC; Eastern Cooperative Oncology Group(ECOG) performance status (PS) 0-1; Measurable disease; Adequate bone marrow, kidney, liver function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962246.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Polish A, Samaras AT, McKoy JM, West DP, Trifilio SM, Tallman J, Talman MS, Bennett CL: Systematic review of toxicities of lineage-specific hematopoietic growth factors toxicities: Implications for biosimilar erythropoietins, thromopoietic receptor agonists, and continuous erythropoietin receptor agonists. J Clin Oncol; 2009 May 20;27(15_suppl):e20733

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although lineage specific hematopoietic growth factors play important roles in the treatment of cancer and chronic kidney disease, recent basic and clinical research studies have identified toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962008.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Dufour JM, Lord SJ, Kin T, Rayat GR, Dixon DE, Bleackley RC, Korbutt GS, Rajotte RV: Comparison of Successful and Unsuccessful Islet/Sertoli Cell Cotransplant Grafts in Streptozotocin-Induced Diabetic Mice. Cell Transplant; 2007 Nov;16(10):1029-1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We cotransplanted 500 BALB/c islets with 1-8 million BALB/c SC under the kidney capsule of diabetic BALB/c, C3H-HeJ, and C57BL/6 mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28866926.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Diabetes / Islet / Sertoli cell / Transplantation
  •  go-up   go-down


25. Loriot Y, Gross-Goupil M, Lesimple T, Blot E, Merrouche Y, Mathieu MC, Fizazi K: Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. J Clin Oncol; 2009 May 20;27(15_suppl):e22168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22168 Background: CUP are an heterogeneous family of neoplasms with a dismal prognosis, with empiric chemotherapy as the recommended treatment.
  • Gene expression profiling was performed using oligonucleotide microarray that contains 495 genes selected as highly differentially expressed between 49 tumor types (CupPrint).
  • Of note, a primary cancer which would not be adequately treated by an empiric chemotherapy regimen currently recommended in CUP (like cisplatin-gemcitabine or carboplatin-paclitaxel) was identified in about half patients: kidney cancer (1), hepatocarcinoma (1), colorectal cancer (3), head and neck cancer (2) and cholangiocarcinoma (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963676.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Rein P, Wöss E, Lhotta K: Renal resistance index-think of more than just the kidney. NDT Plus; 2010 Jun;3(3):333-334

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal resistance index-think of more than just the kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Transplant. 2006 Nov;6(11):2721-4 [17049059.001]
  • [Cites] Ann Thorac Surg. 2009 Nov;88(5):1484-91 [19853098.001]
  • [Cites] NDT Plus. 2009 Dec;2(6):495-7 [25949389.001]
  • (PMID = 28657064.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; kidney transplantation / resistance index / vascular graft
  •  go-up   go-down


27. Rivera M, Ponte B, Felipe C, Liaño F, Ortuño J: Renal ultrasound in acute kidney injury: long-term findings. NDT Plus; 2008 Apr;1(2):127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal ultrasound in acute kidney injury: long-term findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Kidney Dis. 2000 Jun;35(6):1021-38 [10845813.001]
  • [Cites] Kidney Int. 2007 Apr;71(7):679-86 [17264879.001]
  • [Cites] J Ultrasound Med. 1982 Mar;1(2):49-52 [6152926.001]
  • [Cites] Am J Kidney Dis. 1998 Oct;32(4):703 [9774138.001]
  • (PMID = 28657038.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Watkins S: Webwise. Nurs Stand; 2010 Oct 27;25(8):30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : The Kidney Patient Guide website is a collaboration between healthcare professionals, writers, multimedia experts and, most importantly, renal failure patients and their families and carers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28034125.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Redmond A: Chronic kidney disease:risk factors, assessment and nursing care. Nurs Stand; 2006 Nov 15;21(10):48-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic kidney disease:risk factors, assessment and nursing care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27959131.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Chronic illness / Chronic renal failure / Kidney disease / Nursing care
  •  go-up   go-down


30. Higher uric acid level among novel risk factors for ESRD. Nurs Stand; 2009 May 20;23(37):16-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Lower haemoglobin, higher serum uric acid level, self-reported history of nocturia and family history of kidney disease are independent risk factors for end-stage renal disease (ESRD).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001668.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Roth AE, Sönmez T, Ünver U: Efficient Kidney Exchange: Coincidence of Wants in Markets with Compatibility-Based Preferences. Am Econ Rev; 2007 Jun;97(3):828-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient Kidney Exchange: Coincidence of Wants in Markets with Compatibility-Based Preferences.
  • Patients needing kidney transplants may have donors who cannot donate to them because of blood or tissue incompatibility.
  • Incompatible patient-donor pairs can exchange donor kidneys with other pairs only when there is a "double coincidence of wants."

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29135211.001).
  • [ISSN] 0002-8282
  • [Journal-full-title] The American economic review
  • [ISO-abbreviation] Am Econ Rev
  • [Language] eng
  • [Grant] International / National Science Founcation / / SES-0616470; International / National Science Foundation / / SES-0616689
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Thomas L: Voices-England has a way to go in supporting and protecting breastfeeding mothers, says Linda Thomas. Nurs Stand; 2006 Nov 08;21(9):26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : The gloriously named David Kidney, Labour MP for Stafford, has been doing his best to get a private member's bill through parliament to protect a woman's right to breastfeed in public.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27986015.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Greer J, Temel J, Admane S, Solis J, Lynch T, Pirl W: Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a retrospective review of outpatient medical records of 2498 patients with metastatic solid tumors seen at an academic cancer center from 10/1/06 through 2/29/08.
  • The sample consisted of patients with metastatic breast, colorectal, non-colorectal gastrointestinal (GI), bladder/kidney, ovarian, prostate, and lung cancers.
  • Code status was documented more frequently in patients with metastatic non-colorectal GI (193/609, 31.7%) and lung (179/583, 30.7%) cancers compared to patients with genitourinary malignancies (bladder/kidney [4/89, 4.5%], ovarian [4/93, 4.3%] and prostate [7/365, 1.9%] cancers).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • GRP-receptor overexpression has been detected in cancer cells and, more recently, also in the vascular bed of selected tumors.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • GRP-receptor expressing tumoral vessels were evaluated in each tumor group for prevalence, quantity (vascular score) and GRP-receptor density.
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.
  • CONCLUSIONS: Tumoral vessels in all evaluated sites overexpress GRP-receptors, suggesting a major biological function of GRP-receptors in the tumor vascular bed.
  • Vascular GRP-receptor expression varies between the tumor-types indicating tumor-specific mechanisms in their regulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Gandhi M, Calahan C, Oishi K, Lacouture M: Unexpected dermatologic toxicities from anticancer therapies: Survivors' perspectives. J Clin Oncol; 2009 May 20;27(15_suppl):e20673

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The remaining 127 (33%) had ovarian, lung, colorectal, prostate, bladder, kidney, or other malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Wiederkehr D, Casciano R, Stern L, Zheng J, Baladi J: Therapeutic care in metastatic renal cell carcinoma during the follow-up phase of the RECORD-1 phase III trial. J Clin Oncol; 2009 May 20;27(15_suppl):e17531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic care in metastatic renal cell carcinoma during the follow-up phase of the RECORD-1 phase III trial.
  • : e17531 Background: Following drug discontinuation for progression or adverse event in a clinical trial for relapsed or stage IV kidney cancer, supportive care including surgery, palliative radiotherapy, or bisphosphonates continue to be recommended by National Comprehensive Cancer Network (NCCN).
  • METHODS: World Health Organization Anatomical Therapeutic Chemical codes or therapeutic names, captured from the follow-up phase in a phase III clinical trial (RECORD-1) of patients with metastatic renal cell carcinoma (mRCC) patients, were used to describe antineoplastic therapies following discontinuation of study drug.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963810.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Gansler T, Comis R, Sharpe K, Tis L, Jin M, Dahlquist K, Kepner J, Hao Y, Cressman G, Naples K: Initial results of a new clinical trial matching service to increase patient participation. J Clin Oncol; 2009 May 20;27(15_suppl):e17504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 757 individuals with available disease site and enrollment information, those with stomach cancer accounted for the most enrollments (25, 24.75% of all enrollments); followed by melanoma (12, 11.88%) and kidney, renal pelvis, bladder, ureter and urethra (also 12, 11.88%), and breast cancer (11, 10.89%).
  • Strategies for eliminating racial disparities, facilitating transportation, and increasing participation among patients with earlier stage disease and more common tumor types must be developed and implemented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963240.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Bredel M, Renfrow J, Yadav A, Alvarez A, Lin D, Scholtens D, He X, Chandler J, Scheck A, Harsh G: Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme. J Clin Oncol; 2009 May 20;27(15_suppl):2028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Functional analyses using LN229, U87, and U118 glioblastoma cells, and human embryonic kidney 293T cells with transgene phenotypes for IκBα.
  • Functional analyses uncover a bona fide tumor suppressor role for IκBα in glioblastoma cells, where it functions to constrain tumorigenic and migratory potential, and induce spontaneous cellular senescence, and apoptosis in response to treatment.
  • Glioblastomas with initially high IκBα expression significantly repress IκBα upon tumor recurrence, suggesting an acquired mechanism to evade its tumor-suppressive and/or chemo-sensitizing effects during tumor progression.
  • CONCLUSIONS: IκBα is a molecular determinant of biological tumor behavior and patient survival in glioblastoma multiforme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964596.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Suh Y, Oh S, Song B, Jung S: Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy for node-positive breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patient was found to have heart or kidney problem before the commencement of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Kidney stones can develop in children after antibiotics. Nurs Stand; 2005 Jan 19;19(19):10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney stones can develop in children after antibiotics.
  • : Children taking the antibiotic ceftriaxone for a seven-day course may develop renal stones, Turkish researchers have found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006511.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Zoccali C, Kramer A, Jager KJ: Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'. NDT Plus; 2010 Jun;3(3):213-224

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'.
  • Chronic kidney disease (CKD) is increasingly recognized as a major public health problem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2004 Jul 20;141(2):95-101 [15262664.001]
  • [Cites] JAMA. 2004 Jun 2;291(21):2616-22 [15173153.001]
  • [Cites] Kidney Int. 2006 Jul;70(1):26-33 [16723985.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]
  • [Cites] Nephrol Dial Transplant. 2005 Sep;20(9):1799-807 [15928100.001]
  • [Cites] Kidney Int. 2006 Aug;70(4):800-6 [16820784.001]
  • [Cites] Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 [14520607.001]
  • [Cites] J Gen Intern Med. 2007 Jul;22(7):1018-23 [17436030.001]
  • [Cites] J Am Soc Nephrol. 2006 Aug;17(8):2275-84 [16790511.001]
  • [Cites] Kidney Int. 2005 Dec;68(6):2837-45 [16316361.001]
  • [Cites] Semin Nephrol. 2002 Nov;22(6):441-8 [12430088.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] J Am Soc Nephrol. 2003 Oct;14(10):2573-80 [14514734.001]
  • [Cites] Kidney Int Suppl. 2005 Dec;(99):S16-9 [16336570.001]
  • [Cites] Nephrol Dial Transplant. 2001 Jun;16(6):1120-9 [11390709.001]
  • [Cites] Pediatr Nephrol. 2006 Mar;21(3):394-9 [16382317.001]
  • [Cites] Nephrol Dial Transplant. 2003 Sep;18(9):1824-33 [12937231.001]
  • [Cites] BMJ. 2006 Nov 18;333(7577):1047 [17062598.001]
  • [Cites] Hypertension. 2003 Nov;42(5):1050-65 [14604997.001]
  • [Cites] Ann Epidemiol. 2007 Jan;17(1):19-26 [17140811.001]
  • [Cites] Pediatr Nephrol. 2007 Dec;22(12):1999-2009 [17310363.001]
  • [Cites] Bull World Health Organ. 2008 Mar;86(3):229-37 [18368211.001]
  • [Cites] Pediatr Nephrol. 2004 Feb;19(2):213-21 [14685843.001]
  • [Cites] J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S131-8 [12819318.001]
  • [Cites] Circulation. 2002 Aug 6;106(6):703-10 [12163431.001]
  • [Cites] Kidney Int Suppl. 2004 Nov;(92):S7-10 [15485425.001]
  • [Cites] Kidney Int. 2007 Jul;72 (1):92-9 [17440495.001]
  • [Cites] Nephrol Dial Transplant. 2006 Aug;21(8):2178-83 [16595584.001]
  • [Cites] Nephrol Dial Transplant. 2001;16 Suppl 7:57-60 [11590259.001]
  • [Cites] Blood Purif. 2007;25(3):219-20 [17384501.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S37-40 [11792760.001]
  • [Cites] PLoS Med. 2004 Oct;1(1):e27 [15526049.001]
  • [Cites] Kidney Int. 2005 Apr;67(4):1489-99 [15780102.001]
  • [Cites] Int J Health Care Finance Econ. 2007 Sep;7(2-3):201-15 [17641969.001]
  • [Cites] J Am Soc Nephrol. 2005 Jan;16(1):180-8 [15563563.001]
  • [Cites] J Am Soc Nephrol. 2004 May;15(5):1300-6 [15100370.001]
  • [Cites] Kidney Int Suppl. 2005 Sep;(98):S25-9 [16108967.001]
  • [Cites] Eur Heart J. 2006 May;27(10):1245-50 [16611670.001]
  • [Cites] Nephrol Dial Transplant. 2007 Mar;22(3):678-80 [17314211.001]
  • [Cites] J Am Soc Nephrol. 2005 Jul;16(7):2134-40 [15901764.001]
  • [Cites] Clin Ther. 2006 Mar;28(3):432-44 [16750458.001]
  • [Cites] J Am Soc Nephrol. 2006 Jul;17(7):2034-47 [16738019.001]
  • [Cites] Pediatr Nephrol. 1997 Aug;11(4):438-42 [9260241.001]
  • [Cites] N Engl J Med. 2004 Sep 23;351(13):1296-305 [15385656.001]
  • [Cites] Pediatrics. 2003 Apr;111(4 Pt 1):e382-7 [12671156.001]
  • [Cites] Kidney Int. 2007 Jan;71(1):53-9 [17091125.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):147-52 [10963260.001]
  • [Cites] Am J Clin Nutr. 2006 Oct;84(4):707-16 [17023695.001]
  • [Cites] Nephrol Dial Transplant. 2006 Jul;21(7):1899-905 [16611686.001]
  • [Cites] Eur Heart J. 2007 Feb;28(4):478-83 [17223665.001]
  • [Cites] Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290 [15114537.001]
  • [Cites] Am J Kidney Dis. 2005 Aug;46(2):225-32 [16112040.001]
  • [Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]
  • [Cites] Semin Nephrol. 2006 Jan;26(1):68-79 [16412831.001]
  • [Cites] Kidney Int. 2005 Dec;68(6):2801-8 [16316356.001]
  • [Cites] Kidney Int Suppl. 2005 Apr;(94):S28-35 [15752236.001]
  • [Cites] JAMA. 2003 Dec 17;290(23):3101-14 [14679273.001]
  • [Cites] J Am Soc Nephrol. 2006 Jun;17(6):1695-702 [16641153.001]
  • (PMID = 28657040.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; CKD / ESRD / epidemiology / public health
  •  go-up   go-down


42. Potrebko P, McCurdy B: Sci-Fri AM: YIS-07: A new paradigm for improving IMRT: Selection of beam orientations by optimizing beam intersection volume. Med Phys; 2008 Jul;35(7Part3):3411

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the gastric case, the coplanar 5-opt plan reduced the right kidney V 20 Gy by 41.1%, 32.1%, and 29.5% compared to the 5-equi, 7-equi, and 9-equi plans.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512894.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Annealing / Cancer / Dosimetry / Intensity modulated radiation therapy / Kidneys / Radiation therapy
  •  go-up   go-down


43. Morigi M, Benigni A, Remuzzi G, Imberti B: The Regenerative Potential of Stem Cells in Acute Renal Failure. Cell Transplant; 2006 Jan;15(1_suppl):111-117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Regenerative Potential of Stem Cells in Acute Renal Failure.
  • Little is known regarding the presence of stem cells in the adult kidney but it is documented that under certain conditions, such as the recovery from acute injury, the kidney can regenerate itself by increasing the proliferation of some resident cells.
  • The origin of these cells is largely undefined; they are often considered to derive from resident renal stem or progenitor cells.
  • Moreover, the contribution of bone marrow-derived stem cells to renal cell turnover and regeneration has been suggested.
  • Recent studies have demonstrated that hematopoietic stem cells were mobilized following ischemia/reperfusion and engrafted the kidney to differentiate into tubular epithelium in the areas of damage.
  • The evidence that mesenchymal stem cells, by virtue of their renoprotective property, restore renal tubular structure and also ameliorate renal function during experimental acute renal failure provides opportunities for therapeutic intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863770.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute renal failure / Kidney repair / Stem cells / Tubular cells
  •  go-up   go-down


44. McPake D: Caring for patients after kidney transplantation. Nurs Stand; 2009 Jan 14;23(19):49-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caring for patients after kidney transplantation.
  • It focuses on kidney transplantation and the nursing role in optimising long-term patient outcomes and quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991203.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; British Nursing Index / Immunosuppressive medications; / Kidney transplantation; / Patient and graft survival
  •  go-up   go-down


45. McGough G: Webwise. Nurs Stand; 2009 Feb 13;23(23):30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than three million people of all ages are living with kidney disease in the UK.
  • The inter-relationship between kidney disease and many other conditions makes it of particular interest to nurses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28085626.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Teutonico A, Libutti P, Lomonte C, Basile C: Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis. NDT Plus; 2010 Jun;3(3):273-275

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis.
  • Here we report the case of a 45-year-old woman treated with CsA for alopecia universalis, who presented a severe myoglobinuric acute kidney injury following the concomitant use of simvastatin.
  • CsA and simvastatin therapy were stopped, and haemodialysis treatment was started (eight daily dialysis sessions) until sufficient kidney function was regained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Anaesthesiol Scand. 2005 Jul;49(6):859-64 [15954972.001]
  • [Cites] Nephron. 1994;68(1):57-62 [7991041.001]
  • [Cites] Kidney Int Suppl. 1995 Dec;52:S63-9 [8587287.001]
  • [Cites] Int J Tissue React. 2005;27(3):107-10 [16372476.001]
  • [Cites] Drug Metab Dispos. 1997 Oct;25(10):1191-9 [9321523.001]
  • [Cites] Int J Cardiol. 2005 May 11;101(1):9-17 [15860377.001]
  • [Cites] Ann Pharmacother. 2002 Feb;36(2):288-95 [11847951.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004413 [18425901.001]
  • [Cites] Transplantation. 1994 Jul 15;58(1):42-5 [8036706.001]
  • [Cites] Am J Kidney Dis. 1996 Nov;28(5):631-67 [9158202.001]
  • [Cites] JAMA. 2003 Apr 2;289(13):1681-90 [12672737.001]
  • [Cites] Curr Opin Pediatr. 2009 Aug;21(4):475-80 [19502982.001]
  • [Cites] J Nephrol. 2002 May-Jun;15(3):317-9 [12113605.001]
  • (PMID = 28657046.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; acute kidney injury / ciclosporin / myoglobinuria / simvastatin
  •  go-up   go-down


47. McIntyre CW, John SG, Jefferies HJ: Advances in the cardiovascular assessment of patients with chronic kidney disease. NDT Plus; 2008 Dec;1(6):383-391

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the cardiovascular assessment of patients with chronic kidney disease.
  • Cardiovascular mortality is grossly elevated in patients with chronic kidney disease (CKD), and is associated with a wide variety of structural and functional abnormalities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephrol Dial Transplant. 1988;3(2):174-80 [3140083.001]
  • [Cites] Physiol Rev. 1995 Jul;75(3):519-60 [7624393.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R226-31 [14500269.001]
  • [Cites] Biogerontology. 2000;1(3):235-46 [11707900.001]
  • [Cites] Ann Noninvasive Electrocardiol. 2008 Apr;13(2):191-207 [18426445.001]
  • [Cites] Br Heart J. 1981 Mar;45(3):248-63 [7008815.001]
  • [Cites] Ren Fail. 2008;30(7):701-9 [18704819.001]
  • [Cites] Am J Kidney Dis. 2004 Jun;43(6):966-75 [15168376.001]
  • [Cites] J Am Coll Cardiol. 1991 Mar 1;17(3):666-9 [1993786.001]
  • [Cites] Nephron Clin Pract. 2004;96(3):c82-7 [15056990.001]
  • [Cites] Acta Biomed. 2007;78(1):6-15 [17687811.001]
  • [Cites] Ann Cardiol Angeiol (Paris). 2004 Mar;53(2):79-90 [15222240.001]
  • [Cites] Kidney Int. 1999 Dec;56(6):2248-53 [10594802.001]
  • [Cites] J Am Soc Echocardiogr. 2006 Nov;19(11):1359-64 [17098139.001]
  • [Cites] Nephrol Dial Transplant. 2006 Mar;21(3):707-14 [16263735.001]
  • [Cites] Hypertension. 1996 Mar;27(3 Pt 1):330-8 [8698434.001]
  • [Cites] J Am Soc Nephrol. 2004 Apr;15(4):1029-37 [15034106.001]
  • [Cites] Ital Heart J. 2004 Aug;5(8):572-80 [15554027.001]
  • [Cites] Kidney Int. 2006 May;69(10):1839-45 [16508657.001]
  • [Cites] Prog Cardiovasc Dis. 2001 Mar-Apr;43(5):399-418 [11251127.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2009-13 [16330564.001]
  • [Cites] Am J Crit Care. 2005 Jan;14(1):40-5 [15608107.001]
  • [Cites] Br J Anaesth. 2001 Aug;87(2):212-22 [11493492.001]
  • [Cites] Nephrol Dial Transplant. 2005 Sep;20(9):1848-53 [15972319.001]
  • [Cites] Circulation. 1991 May;83(5):1676-84 [1827056.001]
  • [Cites] J Hypertens. 2007 Jan;25(1):163-8 [17143188.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):1212-20 [15327420.001]
  • [Cites] Circulation. 1997 May 20;95(10):2423-33 [9170406.001]
  • [Cites] Cardiol Clin. 2004 May;22(2):221-31 [15158936.001]
  • [Cites] J Am Coll Cardiol. 2005 Jun 21;45(12 ):2034-41 [15963406.001]
  • [Cites] Am J Kidney Dis. 2003 May;41(5):1016-25 [12722036.001]
  • [Cites] Clin Auton Res. 2004 Aug;14 (4):233-9 [15316840.001]
  • [Cites] Clin Physiol Funct Imaging. 2008 Jul;28(4):262-9 [18384622.001]
  • [Cites] Int Angiol. 1996 Mar;15(1):33-8 [8739534.001]
  • [Cites] Clin Sci (Lond). 1997 Apr;92(4):351-9 [9176033.001]
  • [Cites] Circulation. 1982 Dec;66(6):1146-9 [6754130.001]
  • [Cites] Kidney Int. 2000 Mar;57(3):1091-9 [10720961.001]
  • [Cites] Nephron. 1996;73(4):544-8 [8856249.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):338-44 [15954925.001]
  • [Cites] Clin Auton Res. 1997 Dec;7(6):279-84 [9430798.001]
  • [Cites] J Am Soc Nephrol. 2006 May;17 (5):1460-5 [16597683.001]
  • [Cites] Am J Med. 1986 Oct;81(4):630-4 [3532789.001]
  • [Cites] Am J Kidney Dis. 1999 Jun;33(6):1080-90 [10352196.001]
  • [Cites] Nephrol Dial Transplant. 1998 Jun;13(6):1499-505 [9641182.001]
  • [Cites] Am J Cardiol. 1997 Apr 1;79(7):921-8 [9104907.001]
  • [Cites] Nephrol Dial Transplant. 2005 Jun;20(6):1140-7 [15827047.001]
  • [Cites] Nephrol Dial Transplant. 2004 Aug;19(8):2053-60 [15161953.001]
  • [Cites] Transplantation. 1990 Jan;49(1):100-3 [2300998.001]
  • [Cites] J Hypertens. 2003 Jan;21(1):3-12 [12544424.001]
  • [Cites] J Am Soc Nephrol. 2005 Dec;16(12):3687-93 [16280473.001]
  • [Cites] Kidney Int. 2006 Jul;70(1):157-64 [16710351.001]
  • [Cites] J Hypertens Suppl. 1999 Jun;17(2):S3-6 [10465060.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1043:299-307 [16037252.001]
  • [Cites] Cardiologia. 1994 Mar;39(3):193-7 [8039198.001]
  • [Cites] Am J Hypertens. 2005 Jul;18(7):995-1000; discussion 1016 [16053998.001]
  • [Cites] Int J Cardiol. 2005 Aug 18;103(2):168-74 [16080976.001]
  • [Cites] J Am Coll Cardiol. 2007 Dec 11;50(24):2285-90 [18068036.001]
  • [Cites] J Magn Reson Imaging. 2007 May;25(5):974-81 [17457797.001]
  • [Cites] Heart. 1999 Feb;81(2):111-3 [9922343.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jul;18(7):1272-80 [12808161.001]
  • [Cites] N Engl J Med. 1991 Sep 19;325(12):836-42 [1875967.001]
  • [Cites] Kidney Int. 2002 Jul;62(1):166-71 [12081575.001]
  • [Cites] Am Heart J. 2003 Jul;146(1):183-8 [12851629.001]
  • [Cites] Am Heart J. 2004 Jun;147(6):1017-23 [15199350.001]
  • [Cites] J Appl Physiol (1985). 1993 May;74(5):2566-73 [8335593.001]
  • [Cites] Circulation. 2008 Mar 18;117(11):1478-97 [18316491.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2687-96 [15297253.001]
  • [Cites] Nephron Clin Pract. 2008;108(2):c121-6 [18223317.001]
  • [Cites] J Am Coll Cardiol. 1990 Feb;15(2):459-74 [2137151.001]
  • [Cites] J Hypertens. 2006 Jan;24(1):143-50 [16331112.001]
  • [Cites] Diabetes. 1999 Jan;48(1):1-9 [9892215.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H583-9 [17384132.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Jan;3(1):19-26 [18003765.001]
  • [Cites] Clin Auton Res. 1997 Jun;7(3):143-8 [9232359.001]
  • [Cites] Clin Physiol Funct Imaging. 2004 Nov;24(6):387-93 [15522049.001]
  • [Cites] Clin Physiol Funct Imaging. 2003 Mar;23(2):72-80 [12641600.001]
  • [Cites] Kidney Int. 2002 Dec;62(6):1921-32 [12427117.001]
  • [Cites] Diabetologia. 2004 Jul;47(7):1324-1330 [15243705.001]
  • [Cites] Hypertension. 1995 Aug;26(2):341-7 [7543454.001]
  • [Cites] J Hypertens. 2005 Apr;23(4):815-23 [15775787.001]
  • [Cites] J Hypertens. 2004 Jul;22(7):1371-80 [15201554.001]
  • [Cites] Circulation. 2005 Mar 8;111(9):1141-7 [15738351.001]
  • [Cites] Intensive Care Med. 2007 Jul;33(7):1191-4 [17458538.001]
  • [Cites] Am J Kidney Dis. 2006 May;47(5):830-41 [16632022.001]
  • [Cites] Trends Pharmacol Sci. 2006 Sep;27(9):503-8 [16876881.001]
  • [Cites] N Engl J Med. 1998 Jul 16;339(3):173-81 [9664095.001]
  • [Cites] J Am Coll Cardiol. 1999 Aug;34(2):441-7 [10440157.001]
  • [Cites] Kidney Int Suppl. 2008 Apr;(108):S119-24 [18379534.001]
  • [Cites] Diabetes Care. 2006 Dec;29(12):2654-9 [17130200.001]
  • [Cites] Metabolism. 2004 Feb;53(2):222-7 [14767875.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1216-25 [17699351.001]
  • [Cites] J Hypertens. 2002 Jul;20(7):1423-9 [12131540.001]
  • (PMID = 28657024.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Keywords] NOTNLM ; cardiovascular disease / chronic kidney disease / imaging / metabolic stress / monitoring
  •  go-up   go-down


48. Should we allow top-up care? Nurs Stand; 2008 Oct 22;23(7):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Ian Jenkins has kidney cancer that has spread to his lungs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006323.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Low J, Smith G, Burns A, Jones L: The impact of end-stage kidney disease (ESKD) on close persons: a literature review. NDT Plus; 2008 Apr;1(2):67-79

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of end-stage kidney disease (ESKD) on close persons: a literature review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephrol Nurs J. 2005 Nov-Dec;32(6):621-31 [16425810.001]
  • [Cites] Nephrol Dial Transplant. 2007 Aug;22 Suppl 7:vii155-64 [17724043.001]
  • [Cites] Nephrol Dial Transplant. 2004 Jun;19(6):1357-60 [15004252.001]
  • [Cites] Am J Kidney Dis. 2006 Jan;47(1):122-30 [16377393.001]
  • [Cites] Perit Dial Int. 2003 Dec;23 Suppl 2:S200-5 [17986549.001]
  • [Cites] Am J Kidney Dis. 2002 Apr;39(4):805-12 [11920347.001]
  • [Cites] J Adv Nurs. 2000 Jun;31(6):1398-408 [10849152.001]
  • [Cites] EDTNA ERCA J. 1999 Apr-Jun;25(2):45-8 [10531884.001]
  • [Cites] Br J Psychiatry. 2007 Feb;190:142-7 [17267931.001]
  • [Cites] Am J Kidney Dis. 2006 Dec;48(6):955-63 [17162150.001]
  • [Cites] Gerontologist. 1980 Dec;20(6):649-55 [7203086.001]
  • [Cites] ANNA J. 1993 Dec;20(6):653-9 [8267409.001]
  • [Cites] Am J Kidney Dis. 2000 Apr;35(4 Suppl 1):S132-40 [10766011.001]
  • [Cites] Scand J Caring Sci. 2006 Jun;20(2):223-8 [16756529.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4):839-46 [11576888.001]
  • [Cites] Int J Psychiatry Med. 1990;20(1):37-48 [2373593.001]
  • [Cites] Psychol Med. 1991 Feb;21(1):237-43 [2047501.001]
  • [Cites] J Clin Nurs. 2006 Apr;15(4):490-7 [16553763.001]
  • [Cites] BMJ. 1999 Jan 23;318(7178):217-23 [9915728.001]
  • [Cites] ANNA J. 1995 Oct;22(5):457-63, 481; discussion 464 [7487188.001]
  • [Cites] ANNA J. 1997 Oct;24(5):527-8, 531-8; discussion 539-40 [9392735.001]
  • [Cites] J Adv Nurs. 1999 Dec;30(6):1312-20 [10583641.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Int J Nurs Stud. 2002 Mar;39(3):269-77 [11864650.001]
  • [Cites] J Health Psychol. 1999 Mar;4(2):259-72 [22021484.001]
  • [Cites] J Palliat Med. 2006 Aug;9(4):977-92 [16910813.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Int J Nurs Pract. 1999 Sep;5(3):132-6 [10769621.001]
  • [Cites] ANNA J. 1996 Feb;23(1):19-26; discussion 27-8 [8702356.001]
  • [Cites] Adv Ren Replace Ther. 1998 Apr;5(2):98-108 [9554543.001]
  • [Cites] ANNA J. 1994 Aug;21(5):237-46, 257; discussion 247 [8080335.001]
  • [Cites] Clin Nurs Res. 2000 May;9(2):177-90 [12162241.001]
  • [Cites] J Nephrol. 2002 Jan-Feb;15(1):54-60 [11936427.001]
  • [Cites] Nephrol Nurs J. 2003 Feb;30(1):59-63 [12674951.001]
  • [Cites] Nephrol Nurs J. 2001 Aug;28(4):411-7, 419; discussion 418-9 [12143463.001]
  • [Cites] Palliat Med. 2005 Jul;19(5):389-96 [16111062.001]
  • [Cites] Clin Rehabil. 2004 Nov;18(7):776-84 [15573834.001]
  • [Cites] J Nephrol. 2004 Nov-Dec;17(6):841-50 [15593060.001]
  • [Cites] BMJ. 2004 May 8;328(7448):1099 [15130977.001]
  • [Cites] Nephrol Nurs J. 2000 Aug;27(4):383-91, 355; discussion 392, 405 [11276629.001]
  • [Cites] Soc Work Health Care. 2001;33(3-4):105-28 [11837357.001]
  • [Cites] Am J Kidney Dis. 2005 Jan;45(1):154-61 [15696455.001]
  • [Cites] J Nurs Manag. 2001 Jul;9(4):231-9 [11472513.001]
  • [Cites] Ann Behav Med. 1997 Fall;19(4):325-32 [9706357.001]
  • [Cites] EDTNA ERCA J. 2002 Jul-Sep;28(3):141-4 [12371739.001]
  • [Cites] Nurs Res. 1984 May-Jun;33(3):157-61 [6563533.001]
  • [Cites] J Palliat Med. 2005 Feb;8(1):79-85 [15662176.001]
  • [Cites] CANNT J. 2005 Jan-Mar;15(1):25-32 [15909774.001]
  • (PMID = 28656996.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Keywords] NOTNLM ; caregiving/caring / end of life care / end-stage kidney disease / review
  •  go-up   go-down


50. Salerrno May KS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M: Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e15532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal atrophy secondary to chemoradiation treatment of abdominal malignancies.
  • : e15532 Background: Information on renal atrophy following abdominal chemoradiation (CRT) is limited.
  • METHODS: Patients who received concurrent CRT to the abdomen between 2002 and 2008 were identified for this study to evaluate change in renal size (RS) and function following CRT.
  • Renal function was assessed by serum creatinine and creatinine clearance (CrCl) using the Cockcroft-Gault formula.
  • The primarily irradiated kidney (PK) was defined as the kidney that received the greater mean kidney dose.
  • Age, gender, hypertension, diabetes, smoking, pre-RT CrCl, and pre-RT RS were not associated with renal atrophy at 12 months post RT.
  • Percent volumes of the PK receiving ≥10Gy (V<sub>10</sub>), 15Gy (V<sub>15</sub>), and 20Gy (V<sub>20</sub>) were significantly associated with renal atrophy at 12 months post RT (p=0.0030, 0.0041, and 0.0046 respectively).
  • CONCLUSIONS: Significant detriments in PK size and renal function were seen following abdominal CRT.
  • V<sub>10</sub>, V<sub>15</sub>, and V<sub>20</sub> were associated with renal atrophy at 12 months post RT.
  • These observations can assist with renal dose constraints in CRT treatment planning for patients at increased risk for renal complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Elmholdt TR, Jørgensen B, Ramsing M, Pedersen M, Olesen AB: Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus; 2010 Jun;3(3):285-287

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case had chronic kidney disease (CKD) Stage 3 and was exposed to 17.5 ml of gadobutrol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 2008 Jun;73(12):1413-8 [18401336.001]
  • [Cites] J Am Soc Nephrol. 2006 Sep;17(9):2359-62 [16885403.001]
  • [Cites] J Magn Reson Imaging. 2009 Dec;30(6):1249-58 [19938037.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):1000-1 [11041404.001]
  • [Cites] Semin Dial. 2008 Mar-Apr;21(2):129-34 [18225999.001]
  • [Cites] Nephrol Dial Transplant. 2009 Dec;24(12):3882-4 [19767635.001]
  • [Cites] Arch Dermatol. 2009 Feb;145(2):183-7 [19221265.001]
  • [Cites] Semin Dial. 2008 Mar-Apr;21(2):135-9 [18226001.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):273-80 [18067485.001]
  • [Cites] Eur J Radiol. 2008 May;66(2):191-9 [18325705.001]
  • (PMID = 28657062.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; chronic kidney disease / contrast-enhanced MRI / gadobutrol / nephrogenic systemic fibrosis
  •  go-up   go-down


52. Easy squeezer wins patent. Nurs Stand; 2008 Nov 12;23(10):8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sue Wood, pictured, kidney transplant nurse at the Royal Free Hampstead NHS Trust, London, designed the device with her engineer husband and a friend who is a product designer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28026516.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. De Wilde K, Peeters P, Praet M, Petrovic M, Vanholder R: Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours. NDT Plus; 2008 Dec;1(6):469-470

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephrol Dial Transplant. 2006 Apr;21(4):1104-8 [16431890.001]
  • [Cites] Eur Radiol. 2001;11(8):1316-28 [11519538.001]
  • [Cites] Circulation. 2006 Apr 11;113(14):1799-806 [16606801.001]
  • [Cites] J Ultrasound Med. 1999 Sep;18(9):581-8 [10478966.001]
  • [Cites] J Am Soc Nephrol. 1994 Mar;4(9):1661-9 [8011975.001]
  • (PMID = 28657014.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Pouliot F, Pantuck AJ, Calimlim B, Dujardin T: Identification of factors predicting loss of renal differential function on the operated kidney after laparoscopic partial nephrectomy. J Clin Oncol; 2009 May 20;27(15_suppl):e16015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of factors predicting loss of renal differential function on the operated kidney after laparoscopic partial nephrectomy.
  • : e16015 Background: Partial nephrectomy (PN) is now the gold standard for small renal mass of less than 4 cm since it prevents renal insufficiency that may occur with radical nephrectomy.
  • The impact of warm ischemis time (WIT) on the operated kidney's renal differential function (RDF) have been poorly studied in the litterature, especially when WIT is less than 30 minutes.
  • We evaluated the effect of WIT and other perioperative factors on RDF function assessed by pre- and post-operative renal scintigraphy.
  • METHODS: Between 2003 and 2008, 182 laparoscopic PN were performed by a single surgeon on patients with two kidneys.
  • Among those, 56 had a MAG3-lasix renal scintigraphy pre- and post-operatively between 7 and 14 days.
  • RESULTS: Medians for age, pre- op creatinine, pre-op GFR (Cockroft formula) and tumor CT-size were 61 years, 83 μM, 83,2 ml/min and 26 mm, respectively.
  • In multivariate analysis, low pre-operative RDF, WIT and intrarenal location of the tumor were associated with a statistically significant loss of RDF (p<0.05).
  • Age, pre-op GFR, tumor CT-size, diabetes and HTN did not predict loss in RDF.
  • CONCLUSIONS: We show that a WIT of less than 32 minutes optimizes the chances of preserving RDF of the operated kidney and that the rate of loss in RDF is higher above 32 minutes.
  • Finally, higher loss in RDF must be expected if the patient has a low pre-operative RDF and intrarenal location of the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Mulholland PJ, Assoku M, Sasieni P: A retrospective survival analysis of whole brain radiotherapy (WBRT) for brain metastases at Mount Vernon Cancer Centre (MVCC). J Clin Oncol; 2009 May 20;27(15_suppl):2068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2068 Background: The primary purpose of this retrospective study was to determine the survival of patients with brain metastases following WBRT with regards to the influence of tumor type, age < 65 versus ≥ 65 (RPA RTOG prognostic factor) and recency of treatment date.
  • METHODS: From treatment records we identified 1,926 patients with brain metastases from solid tumors who were treated with WBRT at MVCC between February 1992 and March 2008.
  • RESULTS: We obtained dates of death for patients with lung (n=804), breast (n=457), colorectal (n=129), skin (n=119), kidney (n=82), and unknown primary (n=124) cancers.
  • 42 patients were excluded from analysis as their tumor types were unspecified.
  • A heterogeneous group of 169 patients with a variety of other primary tumor types were also excluded from our primary analyses.
  • Log-rank analysis of age < 65 versus ≥ 65 demonstrated improved survival for the former for the colorectal, lung, and skin tumor types (p = 0.0048, 0.0001, and 0.0456 respectively).
  • This relationship did not reach significance for the breast, unknown primary, and renal cancer groups (p = 0.14, 0.13, and 0.06 respectively).
  • CONCLUSIONS: Our data validate age as an important prognostic factor for many tumor types with notable exceptions for as yet undetermined reasons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964683.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kotsakis AP, Tarhini A, Petro D, Flaugh R, Vallabhaneni G, Belani CP, Friedland D, Argiris A: Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8107 Background: Everolimus (E) is an oral inhibitor of mammalian target of rapamycin (mTOR), a novel target for anti-cancer therapy that plays a central role in the PI3K/AKT signaling pathway and other pathways that mediate tumor growth, proliferation, and angiogenesis.
  • METHODS: Eligibility included SCLC with disease progression after up to 2 prior chemotherapy regimens, ECOG performance status (PS) 0-2, and adequate bone marrow, liver, and kidney function.
  • PI3K/AKT signaling pathway molecular biomarkers (AKT, pAKT, PTEN, P-S6, p-4E- BP1) will be evaluated on baseline tumor tissue.
  • Grade 3 toxicities included thrombocytopenia (2), neutropenia (2), infection (1), pneumonitis (1), fatigue (1), elevated transaminases (1), hyperglycemia (1), diarrhea (1), and acute renal failure due to dehydration from diarrhea and poor oral intake (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964287.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Cella D, Michaelson MD, Cappelleri JC, Bushmakin AG, Charbonneau C, Kim ST, Li JZ, Motzer RJ: Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results. J Clin Oncol; 2009 May 20;27(15_suppl):6529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results.
  • QOL was measured by the Functional Assessment of Cancer Therapy-General (FACT-G), which has 4 subscales, the FACT-Kidney Symptom Index-15 item (FKSI-15), which includes a Disease-Related Symptoms (FKSI-DRS) subscale, and the EQ-5D questionnaire's utility index (EQ-5D Index) and visual analog scale (EQ-VAS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964035.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Jian W, Levitt JM, Lerner SP, Sonpavde G: Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinoma (TCC). J Clin Oncol; 2009 May 20;27(15_suppl):e16018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16018 Background: Conventional cisplatin every 3 weeks is frequently precluded in patients with TCC due to renal dysfunction.
  • A metronomic schedule of other chemotherapeutic agents demonstrates anti-angiogenic and anti-tumor activity coupled with better tolerability.
  • Then, 3 groups of tumor-bearing mice received either no therapy, cisplatin 6 mg/kg weekly or cisplatin 2 mg/kg for 3 days a week for up to 6 weeks.
  • Tumor size is measured twice a week.
  • Nephrotoxicity is assessed by serum creatinine and kidney histopathological examination.
  • Cisplatin 4 mg/kg weekly inhibited tumor growth, induced higher apoptosis and down-regulated angiogenesis and proliferation in vivo compared to controls.
  • Results from the experiment comparing cisplatin 6 mg/kg weekly with 2 mg/kg 3 days a week (i.e. more metronomic, with potentially more anti-angiogenic and anti-tumor activity and less nephrotoxic) will be presented.
  • CONCLUSIONS: A metronomic schedule of cisplatin inhibits tumor growth and demonstrates anti-angiogenic activity in a preclinical model of human TCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Zhang J, Lee JS, Urba S, Worden F: A phase II trial evaluating weekly docetaxel and capacitabine in patients with metastatic or advanced, locally, recurrent head and neck cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase I studies combining docetaxel and capacitabine demonstrated anti-tumor effects in breast, colon, and bladder cancers.
  • METHODS: To be eligible for this single arm safety/efficacy phase II study, patients must have documented measurable advanced, locally recurrent or metastatic head and neck cancers, which were untreatable by surgical resection or radiation therapy, a Zubrob performance status of 0-2, adequate marrow, hepatic and kidney functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961916.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Evens AM, David KA, Helenowski I, Kircher SM, Mauro L, Gimelfarb A, Hattersley E, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):8510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 81 PTLD pts were identified (SOT: 47 kidney ± pancreas, 4 pancreas, 17 liver, 8 heart, 5 lung) with median age at diagnosis (dx) of 48 yrs (range 20-72).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S: Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States. J Clin Oncol; 2009 May 20;27(15_suppl):e17556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States.
  • : e17556 Background: RCC, the most prevalent kidney cancer, is a relatively rare malignancy that carries a poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Hofmann R: Incidence and long term prognosis of papillary renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and long term prognosis of papillary renal cell carcinoma.
  • : e16020 Background: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non clear-cell kidney cancer.
  • In this study we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).
  • METHODS: We evaluated 744 patients who had undergone renal surgery for RCC between 1990 and 2005.
  • RESULTS: Both groups pRCC and ccRCC were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis.
  • Even though patients with pRCC presented more often with smaller (p = 0.039) and low grade tumours (p = 0.006), there was no statistically significant difference in tumour recurrence or tumour related death.
  • Moreover, looking at the whole cohort Kaplan-Meier curves revealed no differences regarding tumour specific survival between pRCC and ccRCC (p = 0.94; 5-year survival 78% vs. 77%).
  • However, we observed a trend towards an improved outcome for organ confined (pT1-2) cancer, but a significantly inferior prognosis for locally advanced stage (pT3-4) and/or metastatic papillary tumours at the time of renal surgery.
  • However, applying multivariate analysis including age, sex, and tumour grade, histology could neither be retained as a significant independent prognostic marker in the metastatic setting (p = 0.068, cox regression analysis) nor in a subgroup analysis focussing on patients with advanced cancer (pT3-4 and/or N+/M+; p = 0.064, cox regression analysis).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Golshayan AR, Elson P, Wood LS, Garcia JA, Dreicer R, Rini BI: Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol; 2009 May 20;27(15_suppl):5043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.
  • : 5043 Background: An important goal of non-curative therapy for mRCC is tumor burden (TB) control.
  • However, the impact of tumor burden characteristics on clinical outcome has not been studied in mRCC pts treated with VEGF-targeted therapy.
  • CT scan images were re-reviewed from baseline, at the time of maximal tumor burden shrinkage (TS), at time of disease progression and at time of last assessment prior to death.
  • Sites of metastases included: lung (87%), mediastinal lymph nodes (52%), retroperitoneal lymph nodes (36%), adrenal (29%), bone (38%), liver (22%), pancreas (14%), kidney (7%), and brain (6%).
  • Total number of metastases <10 (p < 0.001) and tumor volume above the diaphragm <6.5 cm (p = 0.05) were independent positive predictors of OS.
  • At time of disease progression (PD), tumor location and pattern of progression were not associated with OS.
  • CONCLUSIONS: Tumor burden shrinkage and tumor burden at time of disease progression are associated with overall survival in pts with mRCC treated with sunitinib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962954.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kirson ED, Weinberg U, Betticher D, Von Moos R, Fischer N, Studt J, Buess M, Burger N, Palti Y, Pless M: A phase I study of tumor treating fields (TTFields) in combination with pemetrexed for pretreated advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e18500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of tumor treating fields (TTFields) in combination with pemetrexed for pretreated advanced non-small cell lung cancer.
  • : e18500 Background: TTFields (tumor treating fields) are low intensity, intermediate frequency, alternating electric fields which slow the growth of solid tumors in-vivo, and have shown promise in pilot clinical trials in patients with advanced solid tumors.
  • Patients with brain metastases were excluded, as were patients with abnormal marrow, kidney, liver or cardiac functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Galili N, Ravandi F, Palermo G, Bubis J, Illingworth A, Castro-Malaspina H, Raza A: Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial. J Clin Oncol; 2009 May 20;27(15_suppl):7082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7082 Background: In patients with PNH, lack of the glycophosphatidylinositol (GPI)-anchored terminal complement inhibitor CD59 on hematopoietic stem cells results in chronic intravascular hemolysis, kidney and pulmonary disorders, thrombosis, and shortened life span.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961475.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Landau HJ, Hoffman J, Hassoun H, Elizabeth H, Riedel E, Nimer SD, Cohen A, Comenzo RL: Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL). J Clin Oncol; 2009 May 20;27(15_suppl):8540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with newly diagnosed AL involving ≤2 organs were assigned to MEL 100, 140 or 200mg/m2 with SCT, based on age, renal function and cardiac involvement.
  • RESULTS: Of 27 pts enrolled, organ involvement was kidney (63%), heart (44%), liver/GI (15%) and peripheral nervous system (7%); 33% have 2 organs involved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960925.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Aasebø W, Strøm EH, Hovig T, Undset LH, Heiberg A, Jenssen T: Fabry disease in donor kidneys with 3- and 12-year follow-up after transplantation. NDT Plus; 2010 Jun;3(3):303-305

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fabry disease in donor kidneys with 3- and 12-year follow-up after transplantation.
  • Enzyme replacement therapy (ERT) has been introduced for Fabry disease and has been reported to clear some renal cell types of accumulated glycolipids and to reduce the accumulation in other cell types.
  • We describe two patients without Fabry disease who were transplanted with kidney allografts from a male donor with Fabry disease.
  • Even though these Fabry kidney allografts for many years had been exposed to normal levels of circulating α-galactosidase A (α-gal-A), the amount of accumulated lysosomal deposits in the podocytes remained unchanged.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1978 Mar;13(3):223-35 [418264.001]
  • [Cites] Am J Transplant. 2007 Dec;7(12):2829-33 [17941959.001]
  • [Cites] Nephron Exp Nephrol. 2007;106(2):e51-9 [17570940.001]
  • [Cites] J Am Soc Nephrol. 2007 May;18(5):1547-57 [17409312.001]
  • [Cites] Kidney Int. 2002 Dec;62(6):1933-46 [12427118.001]
  • [Cites] J Inherit Metab Dis. 2001;24 Suppl 2:66-70; discussion 65 [11758681.001]
  • (PMID = 28657066.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Fabry disease / enzyme replacement therapy / histological changes / kidney / transplantation
  •  go-up   go-down


68. Juang JH, Kuo CH, Wu CH, Juang C: Exendin-4 Treatment Expands Graft β-Cell Mass in Diabetic Mice Transplanted with a Marginal Number of Fresh Islets. Cell Transplant; 2008 Jun;17(6):641-647

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28845709.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Diabetes mellitus / Exendin-4 / Islet transplantation / β-Cell mass
  •  go-up   go-down


69. Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y: Radiation dose estimation using preclinical imaging with I124-metaiodobenzylguanidine (MIBG) PET. Med Phys; 2010 Sep;37(9):4861-4867

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A pretherapyI124-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT) provides a potential method to estimate radiation dose to normal organs, as well as tumors prior to I131-MIBG treatment of neuroblastoma or pheochromocytoma.
  • The tumors did not accumulate I124-MIBG to a detectable level.
  • Volumes of interest were drawn on the coregistered CT images for thyroid, heart, lung, liver, kidney, and bladder, and transferred to PET images to obtain pharmacokinetic data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524557.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Dosimetry / Heart / Liver / Medical imaging / PET / Positron emission tomography / Positron emission tomography (PET) / Radioactivity / Registration / Tissues / dosimetry / image registration / iodine-124 / metaiodobenzylguanidine (MIBG) / neuroblastoma / positron emission tomography / tumours
  •  go-up   go-down


70. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 11 patients received kidney, two lung and one liver, one heart and one pancreas transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Grozav AG, Willard B, Kinter M, Vaziri SA, Bukowski RM, Rini BI, Ganapathi MK, Ganapathi R: Target identification by phosphoproteomics: RIN1 modulation of sorafenib-induced cytotoxicity in renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e14543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target identification by phosphoproteomics: RIN1 modulation of sorafenib-induced cytotoxicity in renal cell carcinoma.
  • : e14543 Background: Sorafenib (SFB) is a multi-tyrosine kinase inhibitor clinically useful in treatment of metastatic renal cancer.
  • METHODS: In this study we used targeted phosphoproteomics to identify tyrosine phosphorylated proteins that are differentially affected in control and SFB-treated human CAKI-1 renal cell carcinoma cells.
  • Similar effects on decreased phosphorylation of STAT1 and RIN1 were also observed in 786-O renal cell carcinoma treated with SFB.
  • CONCLUSIONS: These results demonstrate that RIN1, a Ras effector protein with multiple biochemical functions, is a target for the anti-tumor effects of SFB in kidney cancer cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963618.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Motokawa I, Horai T, Mun M, Sakao Y, Okumura S, Nakagawa K, Nishio M: A phase II study of S-1 for previously treated small cell lung cancer (SCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19074 Background: S-1 is a novel oral 5-fluorouracil derivative that exhibits obvious activity against various tumor types including NSCLC.
  • METHODS: Eligible patients had pathologically documented SCLC that relapsed after platinum-based chemotherapy, ECOG performance status (PS) 0-2, and adequate bone marrow, kidney and liver function.
  • The primary end point was the objective tumor response rate (RECIST).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962213.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Saleem A, Ranson M, Callies S, Lahn M, Prenant C, Brown G, Matthews JC, Dence CS, McMahon A, Price P: Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): A novel paradigm in clinical drug development. J Clin Oncol; 2009 May 20;27(15_suppl):3578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [<sup>11</sup>C]LY2181308 uptake in normal tissue and tumour was quantified.
  • Despite its large size (6778 amu), [<sup>11</sup>C]LY2181308 rapidly distributed to tissues, with maximal uptake in kidney followed by liver, spleen, vertebral body, tumour, spinal cord, lung, and muscle at baseline.
  • Although renal uptake was high, urinary elimination (bladder activity) was low suggesting renal trapping of [<sup>11</sup>C]LY2181308 at baseline.
  • For a normalised injected dose of 1 mg, mean (range) tumour concentrations of 31 (4-41) ng/ml were observed at baseline, consistent with that predicted from the preclinical PK/PD model.
  • In a pt with mesothelioma who also had a second [<sup>11</sup>C]LY2181308-PET scan during LY2181308 treatment infusion, there was about 2-fold increase in [<sup>11</sup>C]LY2181308 tumour uptake, in contrast to markedly reduced uptake in kidneys, liver, and spleen and similar aortic (circulatory) [<sup>11</sup>C]LY2181308 levels.
  • In this patient, tumour [<sup>18</sup>F]FDG- PET uptake at 28 days was reduced by up to 40% after treatment, suggesting drug activity.
  • CONCLUSIONS: [<sup>11</sup>C]LY2181308 pharmacokinetics suggest biologically active human tumour drug concentrations can be attained.
  • LY2181308 therapy saturated normal tissue kinetics and increased tumour uptake of [<sup>11</sup>C]LY2181308.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Weese J, Sandhu PD, Mody A, Ozer H, Jafari M, Tfayli AH, Kojouri K: Assessment of diabetes mellitus (DM) as a risk factor for development of cisplatin-induced nephrotoxicity (CIN). J Clin Oncol; 2009 May 20;27(15_suppl):e13537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13537 Background: DM is the most common cause of kidney disease in the US, and it may increase the risk of CIN.
  • This may be explained by dysfunction of organic cation transporter-2, the critical transporter for cisplatin uptake in proximal tubules, in diabetic kidneys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Hruby G, Van Batavia J, Wosnitzer M, Benson M, Desai M, McKiernan J, Newhouse J: Association of estimated glomerular filtration rate (eGFR) with odds of a renal lesion. J Clin Oncol; 2009 May 20;27(15_suppl):e16025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of estimated glomerular filtration rate (eGFR) with odds of a renal lesion.
  • : e16025 Background: Patients with ESRD on long term hemodialysis are known to be at an increased risk for renal cell carcinoma.
  • We postulate that some component of chronic renal failure not corrected by dialysis might be the tumor-inducing factor.
  • We sought to determine if chronic renal insufficiency is a risk factor for developing renal cell carcinoma.
  • METHODS: A case- control study was used to determine a relationship between renal carcinoma and glomerular filtration rate (MDRD) (eGFR) and using patients with prostate cancer as controls.
  • 1,298 patients from the Columbia University Urologic Oncology Database were identified with either prostate or kidney cancer who had sufficient information to predict eGFR. eGFR calculations were performed for both groups. eGFR was divided into two groups based upon the cut-off value of ≥90. eGFR was also categorized according to the MDRD definitions of chronic kidney disease (CKD), CKD1-4 (values≥90, 60≤values<90, 30≤values<60, and values<30, respectively).
  • Logistic regression techniques were used to quantify the association between pre-operative glomerular filtration rate and the presence of renal or prostate cancer.
  • RESULTS: The mean age of the prostate (n=713) and kidney (n=585) group was 59.9 and 61 years, respectively (p=0.041).
  • The first model found eGFR <90 was significantly associated with the presence of a renal carcinoma when controlling for age and race (OR=1.93, CI=1.49-2.49).
  • The second model investigated the eGFR-CKD categories while controlling for age and race and was able to predict the presence of renal cancer (p < 0.001).
  • Patients with an eGFR value of 60≤X<90 had an OR of 1.47 (CI= 1.13-1.92) for renal cancer when compared to patients with normal eGFR levels.
  • CONCLUSIONS: Diminished renal function showed a significant association with the presence of renal cancer.
  • Chronic renal insufficiency may be a risk factor for the development of renal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Samimi S, Antignac G, Combe C, Lacombe D, Renaud Rougier MB, Korobelnik JF: Bilateral macular detachment caused by bilateral optic nerve malformation in a papillorenal syndrome due to a new PAX2 mutation. Eur J Ophthalmol; 2008 Jul-Aug;18(4):656-658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Papillorenal syndrome is an autosomal dominant entity due to PAX2 gene mutation, involving optic nerve and renal malformations.
  • A medical history of vesicoureteric reflux and kidney hypoplasia led to genetic analysis.
  • CONCLUSIONS: PAX2 is involved in the optic vesicles, genital tracts, kidney, and central nervous system embryogenic development.
  • The association of optic nerve and renal malformations should lead to the suspicion of papillorenal syndrome with PAX2 mutation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221651.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


77. Wosnitzer M, Lee DJ, Hirsch AJ, McKiernan JM: Predictors of renal function in nephron sparing surgery for renal cell carcinoma in solitary kidneys. J Clin Oncol; 2009 May 20;27(15_suppl):e16045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of renal function in nephron sparing surgery for renal cell carcinoma in solitary kidneys.
  • : e16045 Background: Partial nephrectomy (PN) is an effective option for the treatment of renal cell carcinoma (RCC) in patients who need to preserve renal function.
  • However, the oncologic safety and functional outcome after PN in solitary kidneys have not been fully examined.
  • We assessed the outcomes after PN, and evaluated predictors of post-operative renal function.
  • METHODS: A retrospective analysis of the Columbia Urologic Oncology database found 1327 patients were treated for RCC from 1988 - 2008, of whom 38 consecutive patients underwent PN on a solitary kidney.
  • Glomerular filtration rate (GFR) was estimated with the Modification of Diet in Renal Disease (MDRD) equation.
  • Severe chronic kidney disease (CKD) and renal failure were defined as GFR of 15-30 cc/min/1.73m2 and GFR<15, respectively.
  • The mean estimated blood loss was 465cc, the mean tumor diameter was 3.9cm, and 6 (17%) of the patients had a positive surgical margin.
  • Recurrence occurred in the kidneys of 4 patients, lung in 3 patients, bone in 3 patients, and the ipsilateral adrenal gland in one patient.
  • Preoperative GFR (HR=1.01, p<0.01) and the volume of kidney removed (HR=0.93, p=0.01) were associated with severe CKD and renal failure on a univariate Cox regression analysis, but were not independent predictors after adjusting for age, race, tumor stage and grade.
  • Preoperative GFR, volume removed, age, tumor stage or grade were not independent predictors of RCC recurrence.
  • CONCLUSIONS: PN in solitary kidneys pose difficult challenges for surgical and clinical management.
  • Nephron sparing surgery for the treatment of RCC is feasible with acceptable morbidity and renal function outcome.
  • The volume of renal parenchyma removed and the preoperative GFR are associated with renal function loss several months after surgery, and may be useful in predicting long-term renal function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963019.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Patrinou A, Malindretos P, Koutroubas G, Anagnostou N, Argiraki E, Syrganis C: A rare retroperitoneal schwannoma in a patient with neurofibromatosis Type 2. NDT Plus; 2010 Jun;3(3):288-290

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis Type 2 (NF2) is a dominantly inherited tumour-prone disorder, characterized by the development of multiple schwannomas, meningiomas and ependymomas.
  • A well-circumscribed heterogenic mass (9.5 × 4 × 4 cm) behind and under the left kidney and extending into the left retroperitoneal space was revealed during a lumbar and retroperitoneal space magnetic resonance imaging (MRI).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2009 May;93(1):61-77 [19430883.001]
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] World J Gastroenterol. 2007 Nov 7;13(41):5521-4 [17907300.001]
  • [Cites] Curr Probl Cancer. 1981 Jul;6(1):1-47 [6266775.001]
  • [Cites] Orphanet J Rare Dis. 2009 Jun 19;4:16 [19545378.001]
  • [Cites] Tumori. 2007 May-Jun;93(3):312-5 [17679473.001]
  • [Cites] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]
  • [Cites] Arch Ophthalmol. 2006 Mar;124(3):379-85 [16534058.001]
  • (PMID = 28657039.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; meningioma / neurofibromatosis Type 2 / retroperitoneal / schwannoma
  •  go-up   go-down


79. Cozzi DA, Zani A: Nephron-sparing surgery in children with primary renal tumor: indications and results. Semin Pediatr Surg; 2006 Feb;15(1):3-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron-sparing surgery in children with primary renal tumor: indications and results.
  • Nephron-sparing surgery (NSS) is the treatment of choice for children with bilateral Wilms' tumor (WT), or with WT on a single kidney, or with WT and a disease of the contralateral kidney, or with benign kidney tumor.
  • The use of NSS in selected children with "low-risk" or stage I "intermediate-risk" WT and a normal contralateral kidney is still controversial.
  • Available data suggest that, in children with WT, NSS does not impair the outcome and has a renal function advantage over nephrectomy.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrons. Wilms Tumor / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458840.001).
  • [ISSN] 1055-8586
  • [Journal-full-title] Seminars in pediatric surgery
  • [ISO-abbreviation] Semin. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


80. Kamar N, Cointault O, Böhler T, Esposito L, Rostaing L: Long-term results of a calcineurin inhibitor-free immunosuppression based on Thymoglobulin® and mycophenolate mofetil in elderly kidney transplant recipients. NDT Plus; 2008 Apr;1(2):130-131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a calcineurin inhibitor-free immunosuppression based on Thymoglobulin® and mycophenolate mofetil in elderly kidney transplant recipients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs Aging. 2001;18(10):751-9 [11735622.001]
  • [Cites] Drugs Aging. 2005;22(5):433-49 [15903355.001]
  • (PMID = 28657028.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Elder G, Kumar KS: Calciphylaxis associated with chronic kidney disease and low bone turnover: management with recombinant human PTH-(1-34). NDT Plus; 2008 Apr;1(2):97-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calciphylaxis associated with chronic kidney disease and low bone turnover: management with recombinant human PTH-(1-34).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 2000 Jul;25(5):389-92 [11012592.001]
  • [Cites] Q Rev Allergy Appl Immunol. 1961 Jul-Aug;15:461-5 [13749962.001]
  • [Cites] Kidney Int. 2002 Jun;61(6):2210-7 [12028462.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50195-202 [14504275.001]
  • [Cites] Vasa. 1998 Aug;27(3):137-43 [9747147.001]
  • [Cites] World J Surg. 2005 May;29(5):632-5 [15827857.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1135-42 [9194765.001]
  • [Cites] Kidney Int. 2001 Jul;60(1):324-32 [11422768.001]
  • [Cites] Perit Dial Int. 1999 May-Jun;19(3):248-52 [10433161.001]
  • [Cites] Clin Nephrol. 1999 Sep;52(3):160-6 [10499311.001]
  • [Cites] Semin Dial. 2002 May-Jun;15(3):172-86 [12100455.001]
  • (PMID = 28657007.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; bone turnover markers / calciphylaxis / chronic kidney disease / low bone turnover / recombinant human PTH-(1–34)
  •  go-up   go-down


82. Viklicky O, Netuka I, Urbanova M, Adamec M, Maly J, Voska L, Pokorna E: Kidney transplantation from a brain-dead heart transplant candidate treated with biventricular assist device: 12-month follow-up. NDT Plus; 2008 Feb;1(1):34-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney transplantation from a brain-dead heart transplant candidate treated with biventricular assist device: 12-month follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplant Proc. 2005 Dec;37(10):4331-3 [16387112.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jun;25(6):971-7 [15144997.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1697-705 [17462383.001]
  • [Cites] Nephrol Dial Transplant. 2000 May;15(5):705-10 [10809815.001]
  • [Cites] Kidney Int. 2006 Feb;69(3):546-52 [16407884.001]
  • [Cites] Transplantation. 2001 Oct 27;72(8):1341-9 [11685100.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):689-95 [17320566.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):36-43 [10653377.001]
  • [Cites] Am J Transplant. 2004 Jan;4(1):144-6 [14678048.001]
  • (PMID = 28656994.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; extended criteria donor pool / kidney transplantation / mechanical circulatory support
  •  go-up   go-down


83. Inci O, Kaplan M, Yalcin O, Atakan IH, Kubat H: Renal angiomyolipoma with malignant transformation, simultaneous occurrence with malignity and other complex clinical situations. Int Urol Nephrol; 2006;38(3-4):417-26
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal angiomyolipoma with malignant transformation, simultaneous occurrence with malignity and other complex clinical situations.
  • Renal angiomyolipoma is a benign kidney tumor, which is characterized by the presence of mature or immature fat tissue, thick-walled blood vessels, and smooth muscles.
  • And also angiomyolipoma could be associated with renal adenocarcinoma in the same kidney.
  • The aim of this study is to show the association of angiomyolipoma with complex clinical situations such as malign transformation, simultaneous occurrence with adenocarcinoma, bilateral tumors with tuberous sclerosis or Wunderlich Syndrome.
  • Our records indicated that radical nephrectomy was performed in three cases of angiomyolipoma in which the differential diagnosis from adenocarcinoma could not be made and in another case of angiomyolipoma, which was associated with adenocarcinoma.
  • Simple nephrectomy was performed in four symptomatic angiomyolipoma cases with tumor size larger than 4 cm and partial nephrectomy in another case.
  • In one case, renal angiomyolipoma was associated with adenocarcinoma in the same kidney.
  • Angiomyolipoma is regarded as a benign tumor of the kidney; however, it may also show aggressive behaviors and rarely transform to sarcoma.
  • It may also exist in the same kidney along with adenocarcinoma or sarcoma.
  • [MeSH-major] Angiomyolipoma / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):523-9 [11914633.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1123-30 [9331283.001]
  • [Cites] Eur Urol. 1984;10(5):345-6 [6519138.001]
  • [Cites] J Urol. 1992 May;147(5):1356-8 [1569683.001]
  • [Cites] Histopathology. 1996 Mar;28(3):277-80 [8729052.001]
  • [Cites] Br J Urol. 1988 Jul;62(1):89-90 [3408879.001]
  • [Cites] J Urol. 1994 Dec;152(6 Pt 1):1988-91 [7966657.001]
  • [Cites] Urology. 1984 Feb;23(2):200-4 [6695492.001]
  • [Cites] Eur Urol. 1997;32(2):175-8 [9286649.001]
  • [Cites] Hum Genet. 1996 Feb;97(2):240-3 [8566961.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] J Urol. 1986 Jun;135(6):1121-4 [3520013.001]
  • [Cites] Br J Urol. 1990 Dec;66(6):585-9 [2265329.001]
  • [Cites] J Urol. 1993 Dec;150(6):1782-6 [8230504.001]
  • [Cites] Eur Urol. 1994;25(3):183-8 [8200399.001]
  • [Cites] J Urol. 1984 Oct;132(4):749-51 [6471224.001]
  • [Cites] Am J Surg Pathol. 1991 Nov;15(11):1083-8 [1928559.001]
  • [Cites] Br J Urol. 1993 Dec;72(6):983-4 [8306177.001]
  • [Cites] Urol Int. 2001;67(1):28-33 [11464112.001]
  • (PMID = 17033887.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. de la Cruz Burgos R, Martel Villagrán J: [Renal oncocytoma. Fundamental radiologic manifestations and enhancement patterns in tri-phase helical CT]. Radiologia; 2007 Mar-Apr;49(2):109-14
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal oncocytoma. Fundamental radiologic manifestations and enhancement patterns in tri-phase helical CT].
  • [Transliterated title] Oncocitoma renal. Manifestaciones radiológicas fundamentales y patrones de captación en tomografía computarizada helicoidal trifásica.
  • OBJECTIVE: Oncocytoma is a relatively uncommon benign kidney tumor.
  • To date, it has been impossible to differentiate this tumor from renal cell carcinoma radiologically, although few articles report on the use of tri-phase CT in this tumor.
  • We describe the triphasic CT findings in these tumors and evaluate whether some characteristics, although not sufficient to ensure the diagnosis, can suggest the possibility of oncocytoma.
  • The diagnosis was made after histological examination of surgical specimens in all cases.
  • RESULTS: All the tumors were found incidentally at ultrasound examination prior to CT study.
  • Tumors all had well-defined borders, and their size ranged from 3 to 15 cm, with a mean diameter of 5.2 cm.
  • One patient had bilateral tumors (2 right and 1 left).
  • All but one of the tumors had a star-shaped scar inside, with a marked lobular pattern in one case.
  • All tumors showed avid uptake, with mean enhancement of 120 HU in the arterial phase and 116 HU in the venous phase.
  • CONCLUSIONS: Although oncocytoma cannot be differentiated from renal cell carcinoma with certainty, the possibility of oncocytoma should be suggested in the case of small tumors with a central scar, without necrosis or infiltration, and an enhancement pattern as described here.
  • Regardless of the size of the tumor, lobular morphology should also suggest this possibility.
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Kidney Neoplasms / radiography. Tomography, Spiral Computed

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403340.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


85. Bölke E, Gripp S, Matuschek C, Hermsen D, Peiper M, Budach W: Use of cystatin C as a marker to detect renal insufficiency in head and neck cancer patients with cisplatin-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e17048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cystatin C as a marker to detect renal insufficiency in head and neck cancer patients with cisplatin-based chemotherapy.
  • : e17048 Background: Knowledge of the usefulness of cystatin C measurement in the detection of chronic kidney disease in patients with head and neck cancer (HNC) is scant.
  • The purpose of this study was to evaluate the ability of plasma cystatin C- and creatinine-based methods to predict glomerular filtration rate (GFR) and classify chronic kidney disease in HNC patients before receiving cisplatin based chemotherapy.
  • Comparisons were made between measured plasma creatinine, cystatin C, creatinine clearance and GFR estimated by the Modification of Diet in Renal Disease (MDRD) formula.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961772.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Lakey JRT, Kin T, Warnock GL, Shapiro AMJ, Tsapogas P, Imes S, Korbutt GS, Kneteman NM, Rajotte RV, Ryan EA: Long-Term Graft Function after Allogeneic Islet Transplantation. Cell Transplant; 2007 Apr;16(4):441-446

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1989 to 1995 we conducted a series of simultaneous islet-kidney transplants in six uremic type 1 diabetic patients.
  • Two female patients with duration of diabetes of 27 and 37 years underwent simultaneous islet-kidney transplant under steroid- and cyclosporine-based immunosuppression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28858603.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immunosuppression / Islet transplantation / Long-term function / Simultaneous islet–kidney transplantation / Type 1 diabetes
  •  go-up   go-down


87. Boini S, Leplege A, Loos Ayav C, Français P, Ecosse E, Briançon S: [Measuring quality of life in end-stage renal disease. Transcultural adaptation and validation of the specific Kidney Disease Quality of Life questionnaire]. Nephrol Ther; 2007 Oct;3(6):372-83
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measuring quality of life in end-stage renal disease. Transcultural adaptation and validation of the specific Kidney Disease Quality of Life questionnaire].
  • [Transliterated title] Mesure de la qualité de vie dans l'insuffisance rénale chronique terminale. Adaptation transculturelle et validation du questionnaire spécifique Kidney Disease Quality of Life.
  • End-stage renal disease has an important impact on the patients' daily life, which can be measured by quality of life questionnaires.
  • The objective of this work was to adapt the Kidney Disease Quality of Life questionnaire (KDQoL) into French and to determine its basic psychometric properties, i.e. validity and reliability.
  • [MeSH-major] Kidney Failure, Chronic / physiopathology. Kidney Failure, Chronic / psychology. Quality of Life. Surveys and Questionnaires
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Attitude to Health. Cognition. Cross-Cultural Comparison. France. Humans. Language. Middle Aged. Pain. Patient Satisfaction. Peritoneal Dialysis. Renal Dialysis

  • Genetic Alliance. consumer health - Kidney Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919640.001).
  • [ISSN] 1769-7255
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


88. Jean G, Chazot C: [The French clinician's guide to the Kidney disease: Improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD)]. Nephrol Ther; 2010 Jun;6(3):151-7
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The French clinician's guide to the Kidney disease: Improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD)].
  • [Transliterated title] L'essentiel des nouvelles recommandations des kidney disease: improving global outcomes (KDIGO) pour les désordres du métabolisme minéral et osseux à l'usage du clinicien francophone.
  • The new recommendations of "Kidney disease: improving global outcomes" for the definition and classification of chronic kidney disease and mineral and bone disorders were released in August 2009.
  • [MeSH-major] Bone Diseases / etiology. Bone Diseases / prevention & control. Calcium Metabolism Disorders / etiology. Calcium Metabolism Disorders / prevention & control. Kidney Diseases / complications. Phosphorus Metabolism Disorders / etiology. Phosphorus Metabolism Disorders / prevention & control

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20399169.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


89. Mohanty D, Jain BK, Agrawal V, Gupta A: Cystic nephroma: a diagnostic dilemma. Saudi J Kidney Dis Transpl; 2010 May;21(3):518-20
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic nephroma (CN) is a rare benign neoplasm of kidney with excellent prognosis.
  • An accurate pre-operative diagnosis differentiating CN from other cystic renal malignancies may be impossible by clinical and radiological examination, and histopathological examination provides the final diagnosis.
  • This report describes two adult patients with large multi-locular cystic renal masses on imaging and the diagnosis of CN was clinched post-operatively by the honeycomb appearance of the cut specimen and the finding of multiple, non-communicating fluid filled cysts lined by cuboidal or flattened epithelial cells and absence of blastemal cells on microscopy.
  • Tumor diameter on cross sectional imaging remains the key parameter for treatment decisions in renal neoplasms, with nephrectomy being preferred for larger lesions.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427881.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


90. Huang KH, Huang CY, Chung SD, Pu YS, Shun CT, Chen J: Malignant epithelioid angiomyolipoma of the kidney. J Formos Med Assoc; 2007 Feb;106(2 Suppl):S51-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant epithelioid angiomyolipoma of the kidney.
  • Angiomyolipoma (AML) is a common benign renal tumor composed of thick-walled blood vessels, smooth muscle, and adipose tissue, but the malignant epithelioid variant is extremely rare.
  • Computed tomography showed a heterogeneously enhanced mass without fat density in the left kidney.
  • The tumor cells were positive for human melanosome-associated protein (HMB-45) on immunohistochemical staining.
  • Epithelioid AML is a potentially aggressive tumor.
  • HMB-45 immunoreactivity is a useful marker to make diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493897.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


91. Zúñiga San Martín C, Dapueto P J, Müller O H, Kirsten L L, Alid A R, Ortiz M L: [Health related quality of life among patients on chronic hemodialysis]. Rev Med Chil; 2009 Feb;137(2):200-7
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evaluación de la calidad de vida en pacientes en hemodiálisis crónica mediante el cuestionario "Kidney Disease Quality of Life (KDQOL-36)".
  • PATIENTS AND METHODS: A cross-sectional multicenter study was carried out, involving 224 patients from five CHD units (3 private and 2 public) in Bio Bio Region, using the Kidney Disease Quality of Life -36 items (KDQOL-36) questionnaire and Karnofsky scale.
  • RESULTS: Physical and Mental scales and subscales of symptoms, effect and the burden of kidney disease subscales rendered scores below 50 (the referential value), in 80%, 61%, 8%, 43% and 80% of evaluations, respectively.
  • [MeSH-major] Health Status. Kidney Failure, Chronic / therapy. Quality of Life. Renal Dialysis. Surveys and Questionnaires / standards

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543641.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Chile
  •  go-up   go-down


92. Yang Y, Nie X, Lu J, Lu XY, Wei YY, Wang H, Han ZH, Chen ZH, Zheng J: [Mixed epithelial and stromal tumor of kidney]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):29-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed epithelial and stromal tumor of kidney].
  • OBJECTIVE: To study the clinicopathological features and differential diagnoses of mixed epithelial and stromal tumor of the kidney.
  • METHODS: Clinical and pathological characteristics of 4 cases of mixed epithelial and stromal tumor of the kidney were studied.
  • Radiologic studies revealed cystic and solid masses involving the kidney.
  • Grossly the tumors had a solid and cyst appearance.
  • Microscopically, the tumors were composed of a mixture of stromal and epithelial elements.
  • Stromal elements essentially consisted of spindle cells, with thick-walled blood vessels and bands of smooth muscle cells as distinctive features of the tumor.
  • CONCLUSIONS: Mixed epithelial and stromal tumor of the kidney is a benign neoplasm with distinct histopathological features.
  • It should be distinguished from many other renal neoplasms.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Glandular and Epithelial / pathology
  • [MeSH-minor] Actins / metabolism. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Muscle, Smooth / metabolism. Nephrectomy / methods. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608646.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


93. Bjerggaard MM, Barstad B: [Two cases of multilocular cystic nephroma, a rare benign tumor of the kidney]. Ugeskr Laeger; 2005 Nov 14;167(46):4379-80
MedlinePlus Health Information. consumer health - Kidney Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of multilocular cystic nephroma, a rare benign tumor of the kidney].
  • [Transliterated title] To tilfaelde af multilokulaer cystisk nefrom, en sjaelden benign nyretumor.
  • MCN is a rare benign tumor of the kidney that is difficult to differentiate from malignant tumor by diagnostic imaging (ultrasound, CT) and cytology on fine-needle aspiration.
  • This is why most cases end up with nephrectomy and diagnosis is based on the histopathological findings.
  • In one of our two cases, a nephrectomy was performed, and in the other the tumor was resected from the kidney.
  • [MeSH-major] Kidney Diseases, Cystic / diagnosis. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Cystadenoma / diagnosis. Cystadenoma / pathology. Cystadenoma / surgery. Diagnosis, Differential. Female. Humans. Middle Aged. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287525.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


94. Ekici AI, Ekici S, Gürel B, Altinok G, Erkan I, Güngen Y: Benign mixed epithelial and stromal tumor of the kidney. ScientificWorldJournal; 2006;6:615-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial and stromal tumor of the kidney.
  • A 51-year-old, perimenopausal, female patient with 1-month history of right flank pain who was diagnosed with a renal mass and underwent nephron-sparing partial nephrectomy is presented.
  • The renal mass was found to be a benign, biphasic tumor composed of an epithelial component, consisting of ducts of variable size scattered within a mesenchymal component, composed of spindle cells arranged in sheets and fascicles.
  • The diagnosis of benign mixed epithelial and stromal tumor of the kidney is rendered.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Nephroma, Mesoblastic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752009.001).
  • [ISSN] 1537-744X
  • [Journal-full-title] TheScientificWorldJournal
  • [ISO-abbreviation] ScientificWorldJournal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Henske EP: Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol; 2005 Jul;20(7):854-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.
  • The renal manifestations of tuberous sclerosis complex (TSC) are remarkably diverse, including polycystic kidney disease, oncocytomas, renal cell carcinomas, and both benign and malignant angiomyolipomas.
  • Benign angiomyolipomas, which can cause spontaneous life-threatening hemorrhage, are by far the most prevalent and the greatest source of morbidity.
  • What is particularly unusual about TSC, setting it apart from virtually all other inherited forms of renal disease, is the abnormalities of both mesenchymal cells (angiomyolipomas) and epithelial cells (cysts, oncocytomas, and carcinomas).
  • Here, we will address the genetic, cellular and biochemical mechanisms that may contribute to the unusually broad spectrum of renal disease in cells with TSC1 or TSC2 mutations, and consider how the TSC signaling pathways may be linked to other renal diseases such as polycystic kidney disease and renal cell carcinoma.
  • [MeSH-major] Angiomyolipoma / etiology. Carcinoma / etiology. Kidney Neoplasms / etiology. Tuberous Sclerosis / complications
  • [MeSH-minor] Humans. Mutation. Repressor Proteins / genetics. Repressor Proteins / metabolism. Signal Transduction. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 May;2(5):281-7 [10806479.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):457-68 [12547704.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6356-65 [12214276.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700 [12922981.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):493-503 [11468687.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8470-6 [12466966.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] Pediatr Radiol. 2002 Sep;32(9):677-80 [12195309.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):180-7 [9500218.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):491-500 [12547707.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2208-16 [9827727.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):663-72 [9630173.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):205-10 [11904337.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29930-7 [15150271.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2675-80 [12750296.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51372-9 [14551205.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1201-8 [8863669.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):823-32 [11336705.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):194-9 [9005987.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Urology. 1991 Apr;37(4):340-3 [2014599.001]
  • [Cites] Eur J Radiol. 1998 May;27(2):131-8 [9639138.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):193-6 [8162074.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1829-32 [7849708.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):924-34 [15327383.001]
  • [Cites] J Pediatr Surg. 1996 May;31(5):729-30 [8861495.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):889-94 [10843294.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1833-4 [7849709.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • (PMID = 15856327.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 43
  •  go-up   go-down


96. Yang XJ, Zhou M, Hes O, Shen S, Li R, Lopez J, Shah RB, Yang Y, Chuang ST, Lin F, Tretiakova MM, Kort EJ, Teh BT: Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol; 2008 Feb;32(2):177-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization.
  • The nature of tubulocystic carcinoma, a rare renal tumor composed of tubular and cystic structures, is poorly understood.
  • It has been suggested that it may represent a low-grade collecting duct carcinoma of the kidney despite the lack of sufficient molecular and pathologic evidence.
  • The aim of this study was to examine the clinical and pathologic features of 13 cases of tubulocystic carcinoma of the kidney.
  • Furthermore, using gene expression microarray analysis, we defined the molecular signature of this tumor by comparing it with other renal tumors in our previously established molecular profile database.
  • Histologically, all 13 tumors were composed of closely packed tubules and cysts of varying sizes separated by fibrovascular septa.
  • The epithelial lining cells of the tubules and cysts in this tumor were characterized by abundant eosinophilic cytoplasm with prominent nucleoli often showing a hobnail appearance.
  • Five of the 13 cases coexisted with papillary renal cell carcinoma (RCC) (n=3) or papillary adenoma (n=2).
  • Therefore, based on its unique pathologic features and molecular signature as well as its biologic behavior to develop metastasis either by itself or in association with papillary RCC, tubulocystic carcinoma of the kidney should be recognized as a distinct subtype of RCC and be distinguished from other malignant and benign cystic lesions of the kidney.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Renal Cell / secondary. Chromosome Aberrations. Cystadenocarcinoma / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 17. Disease-Free Survival. Female. Fluorescent Antibody Technique, Indirect. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasms, Multiple Primary. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223319.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Coppenrath EM, Mueller-Lisse UG: Multidetector CT of the kidney. Eur Radiol; 2006 Nov;16(11):2603-11
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidetector CT of the kidney.
  • The technological development of multidetector CT offers new possibilities for better imaging of organic structures that can be used in diagnosis of the kidney.
  • Faster scanning allows studies in different contrast phases, which is helpful for better discrimination of benign or malignant lesions especially in the highly vascularized kidney.
  • Indications for CT investigation of the kidney include urolithiasis, tumor diagnosis and staging, renal trauma, and vascular disease.
  • Even in children, special indications for CT of the kidney remain in polytrauma and tumor staging.
  • Multidetector CT of the kidney has become a very valuable tool in urology, but a careful protocol strategy is mandatory.
  • [MeSH-major] Kidney Diseases / diagnostic imaging. Kidney Diseases / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media / administration & dosage. Humans. Image Processing, Computer-Assisted / methods. Neoplasm Staging. Radiation Dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 2001 Oct;21 Spec No:S237-54 [11598260.001]
  • [Cites] Eur Radiol. 2005 Sep;15(9):1834-40 [15761715.001]
  • [Cites] Eur Radiol. 1999;9(5):935-6 [10369994.001]
  • [Cites] Rofo. 2001 Jan;173(1):52-6 [11225418.001]
  • [Cites] Radiology. 2004 Jul;232(1):126-32 [15220498.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):64-8 [15665685.001]
  • [Cites] Radiol Med. 2001 Jun;101(6):459-65 [11479443.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1271-7 [12704036.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):849-55 [11566687.001]
  • [Cites] Eur Radiol. 2001;11(5):779-86 [11372607.001]
  • [Cites] Invest Radiol. 2005 Mar;40(3):126-33 [15714087.001]
  • [Cites] AJR Am J Roentgenol. 2002 May;178(5):1058-62 [11959701.001]
  • [Cites] J Vasc Interv Radiol. 2001 Jan;12(1):3-9 [11200350.001]
  • [Cites] Eur Radiol. 2001;11(7):1140-6 [11471601.001]
  • [Cites] Eur Radiol. 2003 Nov;13(11):2513-20 [12898174.001]
  • [Cites] J Urol. 2002 Apr;167(4):1687-91 [11912388.001]
  • [Cites] AJR Am J Roentgenol. 1999 Sep;173(3):747-55 [10470916.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L116-29 [15018176.001]
  • [Cites] Radiology. 2003 Nov;229(2):575-80 [14526095.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1667-74 [16583216.001]
  • [Cites] Radiology. 1997 Mar;202(3):709-11 [9051021.001]
  • [Cites] Eur Radiol. 2000;10(11):1716-21 [11097395.001]
  • [Cites] Eur Radiol. 2004 Mar;14 Suppl 3:E168-83 [14749952.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):819-21 [9275903.001]
  • [Cites] Radiology. 1997 Jan;202(1):211-7 [8988213.001]
  • [Cites] Eur Urol. 1991;19(2):109-13 [2022212.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):557-74 [11353106.001]
  • [Cites] Med Phys. 2005 Jun;32(6):1621-9 [16013721.001]
  • [Cites] CA Cancer J Clin. 1996 Sep-Oct;46(5):284-302 [8806394.001]
  • [Cites] Radiology. 1997 Jul;204(1):19-25 [9205217.001]
  • [Cites] Radiology. 1999 Apr;211(1):87-94 [10189457.001]
  • [Cites] Eur Radiol. 2004 Jun;14 (6):990-4 [14872276.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1261-7 [9574598.001]
  • [Cites] Radiology. 1995 Aug;196 (2):445-51 [7617859.001]
  • [Cites] Radiology. 2003 Aug;228(2):319-29 [12819343.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):305-11 [12540420.001]
  • [Cites] J Urol. 1985 Dec;134(6):1094-6 [4057398.001]
  • [Cites] Acta Radiol. 2000 Jul;41(4):361-6 [10937759.001]
  • [Cites] BJU Int. 2005 May;95(7):939-42 [15839908.001]
  • [Cites] Eur J Radiol. 2002 Aug;43(2):139-45 [12127211.001]
  • [Cites] Can J Surg. 1990 Dec;33(6):488-90 [2253127.001]
  • [Cites] Radiographics. 2001 Oct;21 Spec No:S201-14 [11598258.001]
  • [Cites] Rofo. 2003 Feb;175(2):211-22 [12584621.001]
  • [Cites] J Comput Assist Tomogr. 2004 May-Jun;28(3):333-9 [15100536.001]
  • [Cites] Radiology. 2002 Dec;225(3):783-90 [12461262.001]
  • [Cites] Radiologe. 2005 Oct;45(10 ):905-14 [16021410.001]
  • [Cites] Urologe A. 1986 Nov;25(6):325-8 [3544449.001]
  • [Cites] Acta Radiol. 2004 May;45(3):301-7 [15239426.001]
  • [Cites] Eur Radiol. 2000;10 (5):783-5 [10823634.001]
  • [Cites] Eur Radiol. 2000;10 (6):897-9 [10879697.001]
  • [Cites] Eur J Radiol. 2004 Oct;52(1):56-66 [15380847.001]
  • [Cites] Radiology. 2005 Apr;235(1):116-23 [15716388.001]
  • (PMID = 16568265.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 57
  •  go-up   go-down


98. Park HS, Kim SH, Kim SH, Paik JH, Hwang SI, Jung SI, Choi YH: Benign mixed epithelial and stromal tumor of the kidney: imaging findings. J Comput Assist Tomogr; 2005 Nov-Dec;29(6):786-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial and stromal tumor of the kidney: imaging findings.
  • Three cases of mixed epithelial and stromal tumor of the kidney with their imaging findings are described; these cases have not been reported previously in the radiology literature.
  • This benign tumor contains epithelial and spindle cell stromal components and arises exclusively in adult women.
  • [MeSH-major] Kidney / pathology. Kidney / radiography. Kidney Neoplasms / diagnosis. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Glandular and Epithelial / diagnosis. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272852.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Bonsib SM, Pei Y: The non-neoplastic kidney in tumor nephrectomy specimens: what can it show and what is important? Adv Anat Pathol; 2010 Jul;17(4):235-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The non-neoplastic kidney in tumor nephrectomy specimens: what can it show and what is important?
  • In the presence of a normal contralateral kidney, such as in a renal transplant donor or child with Wilms tumor, it is a benign procedure without deleterious consequences on the remaining kidney.
  • However, many adults and some children postnephrectomy will develop chronic kidney disease.
  • The non-neoplastic kidney in tumor resections may harbor a large number of developmental and acquired diseases predictive of this outcome or that convey other medically significant information.
  • Examination of the non-neoplastic kidney is a fertile opportunity to identify these unsuspected conditions that may ultimately dictate the subsequent clinical course and influence the medical care provided.
  • [MeSH-major] Kidney / pathology. Kidney Diseases / etiology. Kidney Neoplasms / surgery. Nephrectomy / adverse effects
  • [MeSH-minor] Adult. Arteriosclerosis / complications. Child. Chronic Disease. Diabetes Complications / complications. Diabetes Complications / pathology. Humans. Kidney Diseases, Cystic / etiology. Kidney Diseases, Cystic / pathology. Lymphangiogenesis. Nephrosclerosis / etiology. Nephrosclerosis / pathology. Wilms Tumor / pathology. Wilms Tumor / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Adv Anat Pathol. 2011 Mar;18(2):173; author reply 174 [21326015.001]
  • (PMID = 20574169.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


100. Moslemi MK: Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update. Urol J; 2010;7(3):141-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for mesoblastic nephroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update.
  • PURPOSE: Our aim was to review the spectrum of usual and unusual clinical and morphologic findings observed in mixed epithelial and stromal tumor of the kidney (MEST).
  • RESULTS: Mixed epithelial and stromal tumor is a relatively rare and distinct neoplasm of the kidney that should be distinguished from other renal neoplasms.
  • Although the overall prognosis is favorable, recurrence and malignant transformation of MEST can occur CONCLUSION: It is difficult to distinguish benign or malignant nature on imaging studies.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans






Advertisement